<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Neuropathol Commun</journal-id><journal-id journal-id-type="iso-abbrev">Acta Neuropathol Commun</journal-id><journal-title-group><journal-title>Acta Neuropathologica Communications</journal-title></journal-title-group><issn pub-type="epub">2051-5960</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7962264</article-id><article-id pub-id-type="publisher-id">1140</article-id><article-id pub-id-type="doi">10.1186/s40478-021-01140-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Expression of an alternatively spliced variant of <italic>SORL1</italic> in neuronal dendrites is decreased in patients with Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Monti</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kjolby</surname><given-names>Mads</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jensen</surname><given-names>Anne Mette G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Mariet</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Reiche</surname><given-names>Juliane</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000f8;ller</surname><given-names>Peter L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Comaposada-Bar&#x000f3;</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zolkowski</surname><given-names>Bartlomiej E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vieira</surname><given-names>C&#x000e1;rmen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>Margarita Melnikova</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Holm</surname><given-names>Ida E.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Valdmanis</surname><given-names>Paul N.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Wellner</surname><given-names>Niels</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>V&#x000e6;gter</surname><given-names>Christian B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lincoln</surname><given-names>Sarah J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nykj&#x000e6;r</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ertekin-Taner</surname><given-names>Nil&#x000fc;fer</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Jessica E.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Nyegaard</surname><given-names>Mette</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4226-3354</contrib-id><name><surname>Andersen</surname><given-names>Olav M.</given-names></name><address><email>o.andersen@biomed.au.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Department of Biomedicine, </institution><institution>Aarhus University, </institution></institution-wrap>H&#x000f8;egh-Guldbergs Gade 10, 8000 Aarhus C, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.417467.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0443 9942</institution-id><institution>Department of Neuroscience, </institution><institution>Mayo Clinic, </institution></institution-wrap>Jacksonville, FL 32224 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.275559.9</institution-id><institution-id institution-id-type="ISNI">0000 0000 8517 6224</institution-id><institution>Department of Biochemistry, </institution><institution>Jena University Hospital, </institution></institution-wrap>Jena, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Department of Clinical Medicine, </institution><institution>Aarhus University, </institution></institution-wrap>Aarhus C, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.415677.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 8878</institution-id><institution>Department of Pathology, </institution><institution>Randers Regional Hospital, </institution></institution-wrap>Randers, Denmark </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution>Department of Medicine, Division of Medical Genetics, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Center for Proteins in Memory - PROMEMO, Danish National Research Foundation, Department of Biomedicine, </institution><institution>Aarhus University, </institution></institution-wrap>Aarhus C, Denmark </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.417467.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0443 9942</institution-id><institution>Department of Neurology, </institution><institution>Mayo Clinic, </institution></institution-wrap>Jacksonville, FL 32224 USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution>Department of Pathology, Institute for Stem Cell and Regenerative Medicine, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>9</volume><elocation-id>43</elocation-id><history><date date-type="received"><day>22</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1"><italic>SORL1</italic> is strongly associated with both sporadic and familial forms of Alzheimer&#x02019;s disease (AD), but a lack of information about alternatively spliced transcripts currently limits our understanding of the role of <italic>SORL1</italic> in AD. Here, we describe a <italic>SORL1</italic> transcript (<italic>SORL1-38b</italic>) characterized by inclusion of a novel exon (E38b) that encodes a truncated protein. We identified E38b-containing transcripts in several brain regions, with the highest expression in the cerebellum and showed that <italic>SORL1-38b</italic> is largely located in neuronal dendrites, which is in contrast to the somatic distribution of transcripts encoding the full-length SORLA protein (<italic>SORL1-fl</italic>). <italic>SORL1-38b</italic> transcript levels were significantly reduced in AD cerebellum in three independent cohorts of postmortem brains, whereas no changes were observed for <italic>SORL1-fl</italic>. A trend of lower 38b transcript level in cerebellum was found for individuals carrying the risk variant at rs2282649 (known as SNP24), although not reaching statistical significance. These findings suggest synaptic functions for <italic>SORL1-38b</italic> in the brain, uncovering novel aspects of <italic>SORL1</italic> that can be further explored in AD research.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s40478-021-01140-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#x02019;s disease</kwd><kwd>SORLA</kwd><kwd><italic>SORL1</italic></kwd><kwd>Alternative splicing</kwd><kwd>Dendritic transcript</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008539</institution-id><institution>CurePSP</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Danish Alzheimer Research Foundation</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Maersk-Moller Foundation</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010809</institution-id><institution>Jascha Fonden</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Aarhus University Graduate School of Health</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>PROMEMO</institution></funding-source><award-id>DNRF133</award-id><principal-award-recipient><name><surname>Nykj&#x000e6;r</surname><given-names>Anders</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Alzheimer's Disease Research Center</institution></funding-source><award-id>AG05136</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Adult Changes in Thought Study</institution></funding-source><award-id>AG006781</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Pacific Udall Center</institution></funding-source><award-id>3P50NS062684</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>DOD</institution></funding-source><award-id>HU00011920008</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>NIA</institution></funding-source><award-id>P50 AG016574</award-id><award-id>R01 AG032990</award-id><award-id>U01 AG046139</award-id><award-id>R01 AG018023</award-id><award-id>U01 AG006576</award-id><award-id>U01 AG006786</award-id><award-id>R01 AG025711</award-id><award-id>R01 AG017216</award-id><award-id>R01 AG003949</award-id><principal-award-recipient><name><surname>Ertekin-Taner</surname><given-names>Nil&#x000fc;fer</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>NINDS</institution></funding-source><award-id>R01 NS080820</award-id><principal-award-recipient><name><surname>Ertekin-Taner</surname><given-names>Nil&#x000fc;fer</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The <italic>SORL1</italic> gene encodes the protein SORLA and is associated with Alzheimer&#x02019;s disease (AD) [<xref ref-type="bibr" rid="CR1">1</xref>]. Recent burden analyses of ultra-rare variants through exome sequencing have found an excess of loss-of-function variants in AD cases, suggesting haploinsufficiency of <italic>SORL1</italic> as a pathogenic mechanism in some patients [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. More recently, <italic>SORL1</italic> missense variants in familial AD have also been reported [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], but the functional consequences of these variants are unknown.</p><p id="Par3">Previous studies have established SORLA as a sorting receptor for the amyloid precursor protein (APP) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. This function depends on the physical contact between the extracellular parts of SORLA and APP, and the ability of the cytoplasmic tail of SORLA to form complexes with intracellular trafficking molecules including the retromer complex [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Apart from its role as an APP trafficking determinant, very limited information exists about SORLA neuronal functions. There is therefore an increasing need to better understand the function of SORLA in the brain.</p><p id="Par4">Alternative splicing (AS) is an essential process significantly involved in the expansion of the transcriptome and protein diversity. As another result of AS, transcripts from the same gene can also have different 3&#x02032; untranslated regions (3&#x02032; UTRs) and/or contain target motifs for RNA binding proteins within exonic sequences, responsible for distinct neuronal trafficking of transcript isoforms to axons or dendrites where they may be locally translated [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Recently, emerging evidence links AS with the maintenance of neuronal homeostasis [<xref ref-type="bibr" rid="CR34">34</xref>], and associations between AS and AD have been reported [<xref ref-type="bibr" rid="CR35">35</xref>]. For this reason, increased attention is directed towards AS of genes involved in neurodegenerative and neuropsychiatric diseases.</p><p id="Par5">Although transcripts from&#x02009;~&#x02009;95% of all human multi-exon genes undergo AS [<xref ref-type="bibr" rid="CR31">31</xref>], surprisingly little is known about the biological relevance for AS of <italic>SORL1</italic>. Due to an increasing number of putative transcripts annotated in databases, it is key to conduct experimental investigations to discriminate between functional transcripts and products derived by transcriptional noise. Here, we provide a detailed characterization of an alternatively spliced <italic>SORL1</italic> transcript. Inclusion of a hitherto undescribed exon leads to transcripts that can be translated into a truncated receptor lacking its transmembrane and cytoplasmic domains, pointing towards a function unrelated to sorting of cargoes including APP. Using brain samples from three independent cohorts, we found decreased transcript expression of this truncating <italic>SORL1</italic> isoform in AD patients, and identified enriched expression in neuronal dendrites suggesting a role of this novel isoform in synaptic plasticity, known to be impaired in AD.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Human samples</title><p id="Par6">We used biological material from four different sources: total RNA acquired from ClonTech, and human postmortem brain tissues from three different brain banks; the Netherlands Brain Bank (NBB), Mayo Clinic (Mayo), and University of Washington (UW).</p><p id="Par7"><italic>From ClonTech,</italic> we obtained total RNA from brain, spinal cord, bone marrow, liver, heart, lung, trachea, kidney, adrenal gland, salivary gland, thyroid gland, thymus, skeletal muscle, colon, prostate, testis, placenta, and uterus.</p><p id="Par8"><italic>From NBB</italic>, postmortem cerebella (n&#x02009;=&#x02009;3 AD; n&#x02009;=&#x02009;3 non-AD), hippocampus (n&#x02009;=&#x02009;3 non-AD) and entorhinal cortex (n&#x02009;=&#x02009;3 non-AD) samples were obtained for in situ hybridization (ISH) (Table <xref rid="Tab1" ref-type="table">1</xref>). NBB procedures have been approved by the ethics committee at the Vrije University Medical Center, Amsterdam, NL. The materials were donated to the bank on the basis of signed informed consent with the restriction of research purposes only. Diagnosis of AD was made by neuropsychological testing, followed by autoptic histopathological confirmation with disease propagation described by Braak staging. Following autopsy, cerebellum was dissected at the level of dentate nucleus, fixed in 4% paraformaldehyde and the tissue was embedded in paraffin blocks.<table-wrap id="Tab1"><label>Table 1.</label><caption><p>Netherlands Brain Bank samples data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Region</th><th align="left">Diagnosis</th><th align="left">Sex</th><th align="left">Age</th><th align="left">PMD</th><th align="left">pH</th><th align="left">Weight</th><th align="left">ApoE</th><th align="left">Braak stage</th></tr></thead><tbody><tr><td align="left">Cerebellum</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">72</td><td align="left">07:25</td><td char="." align="char">6.61</td><td align="left">1370</td><td align="left">3/3</td><td align="left">0</td></tr><tr><td align="left">Cerebellum</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">69</td><td align="left">05:55</td><td char="." align="char">6.41</td><td align="left">1450</td><td align="left">3/3</td><td align="left">0</td></tr><tr><td align="left">Cerebellum</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">62</td><td align="left">09:35</td><td char="." align="char">6.58</td><td align="left">1163</td><td align="left">3/3</td><td align="left">0</td></tr><tr><td align="left">Cerebellum</td><td align="left">AD</td><td align="left">M</td><td align="left">75</td><td align="left">04:20</td><td char="." align="char">6.91</td><td align="left">1325</td><td align="left">3/3</td><td align="left">6</td></tr><tr><td align="left">Cerebellum</td><td align="left">AD</td><td align="left">M</td><td align="left">58</td><td align="left">05:10</td><td char="." align="char">6.99</td><td align="left">1180</td><td align="left">3/3</td><td align="left">6</td></tr><tr><td align="left">Cerebellum</td><td align="left">AD</td><td align="left">M</td><td align="left">69</td><td align="left">05:30</td><td char="." align="char">6.18</td><td align="left">1086</td><td align="left">3/3</td><td align="left">6</td></tr><tr><td align="left">Hippocampus</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">91</td><td align="left">08:00</td><td char="." align="char">6.26</td><td align="left">1188</td><td align="left">3/3</td><td align="left">1</td></tr><tr><td align="left">Hippocampus</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">79</td><td align="left">05:45</td><td char="." align="char">6.38</td><td align="left">1361</td><td align="left">3/3</td><td align="left">2</td></tr><tr><td align="left">Hippocampus</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">96</td><td align="left">04:10</td><td char="." align="char">6.09</td><td align="left">1250</td><td align="left">3/3</td><td align="left">4</td></tr><tr><td align="left">Amygdala/EC</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">81</td><td align="left">07:55</td><td char="." align="char">6.23</td><td align="left">1194</td><td align="left">3/3</td><td align="left">2</td></tr><tr><td align="left">Amygdala/EC</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">78</td><td align="left">&#x02009;&#x0003c;&#x02009;17:40</td><td char="." align="char">6.52</td><td align="left">1125</td><td align="left">3/3</td><td align="left">1</td></tr><tr><td align="left">Amygdala/EC</td><td align="left">Non-AD</td><td align="left">M</td><td align="left">79</td><td align="left">05:45</td><td char="." align="char">6.38</td><td align="left">1361</td><td align="left">3/3</td><td align="left">2</td></tr></tbody></table><table-wrap-foot><p><italic>PMD</italic> post-mortem delay</p></table-wrap-foot></table-wrap></p><p id="Par9"><italic>From Mayo Clinic</italic>, postmortem brain samples (n&#x02009;=&#x02009;25 AD; n&#x02009;=&#x02009;25 non-AD) were obtained for qPCR as previously described [<xref ref-type="bibr" rid="CR5">5</xref>] and eQTL analysis (Table <xref rid="Tab2" ref-type="table">2</xref>). Briefly, non-AD control samples had a Braak score of 3.0 or less and lacked any other major pathologic diagnoses; AD patients had a Braak score of&#x02009;&#x02265;&#x02009;4.0 and a definite diagnosis according to the NINCDS-ADRDA criteria [<xref ref-type="bibr" rid="CR27">27</xref>]. Individuals were age matched across diagnosis groups (&#x000b1;&#x02009;1&#x000a0;year), were older than 60&#x000a0;years at time of death and 48% of each diagnosis group were male. This study was approved by the appropriate institutional review board.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Mayo Clinic cohort data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Sample id</th><th align="left">Diagnosis</th><th align="left">Age at death</th><th align="left">Gender</th><th align="left">RIN</th><th align="left">GENOTYPE_rs2282649</th></tr></thead><tbody><tr><td align="left">14546_CER</td><td align="left">Non-AD</td><td char="." align="char">83</td><td align="left">M</td><td char="." align="char">8.3</td><td align="left">C/C</td></tr><tr><td align="left">14548_CER</td><td align="left">Non-AD</td><td char="." align="char">83</td><td align="left">M</td><td char="." align="char">8.5</td><td align="left">C/C</td></tr><tr><td align="left">14549_CER</td><td align="left">Non-AD</td><td char="." align="char">63</td><td align="left">M</td><td char="." align="char">8.8</td><td align="left">C/C</td></tr><tr><td align="left">14551_CER</td><td align="left">Non-AD</td><td char="." align="char">80</td><td align="left">F</td><td char="." align="char">9.3</td><td align="left">C/C</td></tr><tr><td align="left">14556_CER</td><td align="left">Non-AD</td><td char="." align="char">72</td><td align="left">F</td><td char="." align="char">8.9</td><td align="left">C/T</td></tr><tr><td align="left">7101_CER</td><td align="left">Non-AD</td><td char="." align="char">79</td><td align="left">M</td><td char="." align="char">7.3</td><td align="left">na</td></tr><tr><td align="left">7104_CER</td><td align="left">Non-AD</td><td char="." align="char">78</td><td align="left">F</td><td char="." align="char">8.6</td><td align="left">na</td></tr><tr><td align="left">14543_CER</td><td align="left">Non-AD</td><td char="." align="char">80</td><td align="left">M</td><td char="." align="char">6.6</td><td align="left">C/C</td></tr><tr><td align="left">14562_CER</td><td align="left">Non-AD</td><td char="." align="char">76</td><td align="left">M</td><td char="." align="char">8.1</td><td align="left">C/T</td></tr><tr><td align="left">1926_CER</td><td align="left">Non-AD</td><td char="." align="char">88</td><td align="left">F</td><td char="." align="char">7.7</td><td align="left">C/C</td></tr><tr><td align="left">1936_CER</td><td align="left">Non-AD</td><td char="." align="char">89</td><td align="left">F</td><td char="." align="char">6.6</td><td align="left">C/T</td></tr><tr><td align="left">1955_CER</td><td align="left">Non-AD</td><td char="." align="char">87</td><td align="left">F</td><td char="." align="char">8.3</td><td align="left">C/C</td></tr><tr><td align="left">1960_CER</td><td align="left">Non-AD</td><td char="." align="char">97</td><td align="left">F</td><td char="." align="char">7.6</td><td align="left">C/C</td></tr><tr><td align="left">1963_CER</td><td align="left">Non-AD</td><td char="." align="char">94</td><td align="left">M</td><td char="." align="char">9.1</td><td align="left">C/T</td></tr><tr><td align="left">1964_CER</td><td align="left">Non-AD</td><td char="." align="char">92</td><td align="left">M</td><td char="." align="char">9.2</td><td align="left">C/C</td></tr><tr><td align="left">14557_CER</td><td align="left">Non-AD</td><td char="." align="char">81</td><td align="left">M</td><td char="." align="char">8.1</td><td align="left">C/T</td></tr><tr><td align="left">1919_CER</td><td align="left">Non-AD</td><td char="." align="char">87</td><td align="left">F</td><td char="." align="char">9.2</td><td align="left">C/T</td></tr><tr><td align="left">1933_CER</td><td align="left">Non-AD</td><td char="." align="char">98</td><td align="left">F</td><td char="." align="char">7.8</td><td align="left">C/C</td></tr><tr><td align="left">1934_CER</td><td align="left">Non-AD</td><td char="." align="char">89</td><td align="left">M</td><td char="." align="char">9.7</td><td align="left">C/T</td></tr><tr><td align="left">1937_CER</td><td align="left">Non-AD</td><td char="." align="char">86</td><td align="left">F</td><td char="." align="char">8.5</td><td align="left">C/C</td></tr><tr><td align="left">1940_CER</td><td align="left">Non-AD</td><td char="." align="char">96</td><td align="left">M</td><td char="." align="char">7.5</td><td align="left">C/C</td></tr><tr><td align="left">1944_CER</td><td align="left">Non-AD</td><td char="." align="char">98</td><td align="left">F</td><td char="." align="char">7.1</td><td align="left">C/C</td></tr><tr><td align="left">1945_CER</td><td align="left">Non-AD</td><td char="." align="char">90</td><td align="left">M</td><td char="." align="char">8.9</td><td align="left">C/C</td></tr><tr><td align="left">1950_CER</td><td align="left">Non-AD</td><td char="." align="char">86</td><td align="left">F</td><td char="." align="char">7.6</td><td align="left">C/T</td></tr><tr><td align="left">1952_CER</td><td align="left">Non-AD</td><td char="." align="char">92</td><td align="left">F</td><td char="." align="char">8.8</td><td align="left">C/T</td></tr><tr><td align="left">1058_CER</td><td align="left">AD</td><td char="." align="char">95</td><td align="left">M</td><td char="." align="char">7.5</td><td align="left">C/C</td></tr><tr><td align="left">1166_CER</td><td align="left">AD</td><td char="." align="char">84</td><td align="left">M</td><td char="." align="char">8.5</td><td align="left">C/T</td></tr><tr><td align="left">142_CER</td><td align="left">AD</td><td char="." align="char">89</td><td align="left">F</td><td char="." align="char">9.2</td><td align="left">C/C</td></tr><tr><td align="left">747_CER</td><td align="left">AD</td><td char="." align="char">62</td><td align="left">M</td><td char="." align="char">8.9</td><td align="left">na</td></tr><tr><td align="left">807_CER</td><td align="left">AD</td><td char="." align="char">81</td><td align="left">M</td><td char="." align="char">7.9</td><td align="left">na</td></tr><tr><td align="left">851_CER</td><td align="left">AD</td><td char="." align="char">87</td><td align="left">F</td><td char="." align="char">9.1</td><td align="left">C/T</td></tr><tr><td align="left">896_CER</td><td align="left">AD</td><td char="." align="char">80</td><td align="left">F</td><td char="." align="char">9.1</td><td align="left">C/C</td></tr><tr><td align="left">1034_CER</td><td align="left">AD</td><td char="." align="char">88</td><td align="left">F</td><td char="." align="char">7.8</td><td align="left">T/T</td></tr><tr><td align="left">1046_CER</td><td align="left">AD</td><td char="." align="char">72</td><td align="left">F</td><td char="." align="char">9.2</td><td align="left">C/C</td></tr><tr><td align="left">1052_CER</td><td align="left">AD</td><td char="." align="char">91</td><td align="left">M</td><td char="." align="char">8.4</td><td align="left">C/T</td></tr><tr><td align="left">1114_CER</td><td align="left">AD</td><td char="." align="char">82</td><td align="left">M</td><td char="." align="char">8.4</td><td align="left">T/T</td></tr><tr><td align="left">1169_CER</td><td align="left">AD</td><td char="." align="char">92</td><td align="left">M</td><td char="." align="char">8.5</td><td align="left">na</td></tr><tr><td align="left">907_CER</td><td align="left">AD</td><td char="." align="char">95</td><td align="left">F</td><td char="." align="char">7.6</td><td align="left">na</td></tr><tr><td align="left">953_CER</td><td align="left">AD</td><td char="." align="char">86</td><td align="left">F</td><td char="." align="char">8.3</td><td align="left">na</td></tr><tr><td align="left">720_CER</td><td align="left">AD</td><td char="." align="char">75</td><td align="left">M</td><td char="." align="char">8.1</td><td align="left">na</td></tr><tr><td align="left">741_CER</td><td align="left">AD</td><td char="." align="char">89</td><td align="left">M</td><td char="." align="char">8.4</td><td align="left">na</td></tr><tr><td align="left">790_CER</td><td align="left">AD</td><td char="." align="char">86</td><td align="left">F</td><td char="." align="char">7.5</td><td align="left">na</td></tr><tr><td align="left">809_CER</td><td align="left">AD</td><td char="." align="char">87</td><td align="left">F</td><td char="." align="char">8.4</td><td align="left">na</td></tr><tr><td align="left">911_CER</td><td align="left">AD</td><td char="." align="char">89</td><td align="left">F</td><td char="." align="char">7.3</td><td align="left">na</td></tr><tr><td align="left">963_CER</td><td align="left">AD</td><td char="." align="char">99</td><td align="left">F</td><td char="." align="char">7.7</td><td align="left">na</td></tr><tr><td align="left">990_CER</td><td align="left">AD</td><td char="." align="char">79</td><td align="left">M</td><td char="." align="char">6.7</td><td align="left">na</td></tr><tr><td align="left">1101_CER</td><td align="left">AD</td><td char="." align="char">78</td><td align="left">M</td><td char="." align="char">7.6</td><td align="left">na</td></tr><tr><td align="left">1146_CER</td><td align="left">AD</td><td char="." align="char">100</td><td align="left">F</td><td char="." align="char">8.5</td><td align="left">C/C</td></tr><tr><td align="left">731_CER</td><td align="left">AD</td><td char="." align="char">93</td><td align="left">M</td><td char="." align="char">9.0</td><td align="left">T/T</td></tr><tr><td align="left">966_CER</td><td align="left">AD</td><td char="." align="char">79</td><td align="left">2</td><td char="." align="char">8.8</td><td align="left">C/T</td></tr></tbody></table><table-wrap-foot><p><italic>RIN</italic> RNA integrity number</p></table-wrap-foot></table-wrap></p><p id="Par10"><italic>From UW</italic>, postmortem cerebella tissue (n&#x02009;=&#x02009;14 AD; n&#x02009;=&#x02009;6 non-AD) were selected for qPCR based on SNP24 genotype (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>University of Washington cohort data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Sample id</th><th align="left">Diagnosis</th><th align="left">Age at death</th><th align="left">Gender</th><th align="left">GENOTYPE_rs2282649</th></tr></thead><tbody><tr><td align="left">1706_CER</td><td align="left">Non-AD</td><td char="." align="char">76</td><td align="left">F</td><td align="left">T/T</td></tr><tr><td align="left">1661_CER</td><td align="left">Non-AD</td><td char="." align="char">92</td><td align="left">F</td><td align="left">C/T</td></tr><tr><td align="left">1776_CER</td><td align="left">Non-AD</td><td char="." align="char">98</td><td align="left">F</td><td align="left">C/T</td></tr><tr><td align="left">1750_CER</td><td align="left">Non-AD</td><td char="." align="char">78</td><td align="left">M</td><td align="left">C/C</td></tr><tr><td align="left">1792_CER</td><td align="left">Non-AD</td><td char="." align="char">93</td><td align="left">F</td><td align="left">C/C</td></tr><tr><td align="left">1814_CER</td><td align="left">Non-AD</td><td char="." align="char">86</td><td align="left">F</td><td align="left">C/C</td></tr><tr><td align="left">1798_CER</td><td align="left">AD</td><td char="." align="char">93</td><td align="left">F</td><td align="left">T/T</td></tr><tr><td align="left">1744_CER</td><td align="left">AD</td><td char="." align="char">93</td><td align="left">F</td><td align="left">T/T</td></tr><tr><td align="left">1745_CER</td><td align="left">AD</td><td char="." align="char">82</td><td align="left">F</td><td align="left">T/T</td></tr><tr><td align="left">1784_CER</td><td align="left">AD</td><td char="." align="char">90+</td><td align="left">F</td><td align="left">T/T</td></tr><tr><td align="left">1785_CER</td><td align="left">AD</td><td char="." align="char">93</td><td align="left">M</td><td align="left">T/T</td></tr><tr><td align="left">1815_CER</td><td align="left">AD</td><td char="." align="char">67</td><td align="left">F</td><td align="left">T/T</td></tr><tr><td align="left">1682_CER</td><td align="left">AD</td><td char="." align="char">100</td><td align="left">F</td><td align="left">C/T</td></tr><tr><td align="left">1733_CER</td><td align="left">AD</td><td char="." align="char">92</td><td align="left">F</td><td align="left">C/T</td></tr><tr><td align="left">1746_CER</td><td align="left">AD</td><td char="." align="char">69</td><td align="left">M</td><td align="left">C/T</td></tr><tr><td align="left">1771_CER</td><td align="left">AD</td><td char="." align="char">98</td><td align="left">F</td><td align="left">C/T</td></tr><tr><td align="left">1806_CER</td><td align="left">AD</td><td char="." align="char">65</td><td align="left">M</td><td align="left">C/T</td></tr><tr><td align="left">1662_CER</td><td align="left">AD</td><td char="." align="char">82</td><td align="left">F</td><td align="left">C/C</td></tr><tr><td align="left">1681_CER</td><td align="left">AD</td><td char="." align="char">74</td><td align="left">F</td><td align="left">C/C</td></tr><tr><td align="left">1707_CER</td><td align="left">AD</td><td char="." align="char">90</td><td align="left">M</td><td align="left">C/C</td></tr><tr><td align="left">1804_CER</td><td align="left">AD</td><td char="." align="char">101</td><td align="left">F</td><td align="left">C/C</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title><italic>SORL1-38b</italic> transcript levels across different human tissues</title><p id="Par11">Total RNA from ClonTech was converted to cDNA using 1&#x000a0;&#x003bc;g of RNA and High Capacity RNA-to-cDNA kit (Cat N. #4387406, Applied Biosystems, Europe). PCR was performed using Herculase II Fusion DNA Polymerase (Cat N. #600675, Agilent, Europe) on a Veriti Thermal Cycler (Applied Biosystems) in the presence of 3% DMSO with the following optimized protocol: 95&#x000a0;&#x000b0;C for 2&#x000a0;min, followed by 35 cycles of amplification (95&#x000a0;&#x000b0;C for 20&#x000a0;s, 52&#x000a0;&#x000b0;C for 20&#x000a0;s and 72&#x000a0;&#x000b0;C for 30&#x000a0;s) and extension at 72&#x000a0;&#x000b0;C for 3&#x000a0;min. <italic>SORL1-38B</italic> was amplified using primers in exon 35 and 38b. Primer sequences were SORL1-Ex35-fw: 5&#x02032;-GGCACACAACACCAATGACT, and SORL1-Ex38B-rev; 5&#x02032;-TGCTCTTCCAACATCCCTTCT. Water was used as negative control. RT-PCR for the analysis of splicing events downstream of E38b was performed using Titanium One-Step RT-PCR Kit (Cat N. 639504, ClonTech) on total RNA from human cerebellum (Cat N. 636535, ClonTech) with primers located in exons 38b and 40. Primer were SORL1-Ex38b-fw: 5&#x02032;-TGACCACACATACCAAGAAGGG and SORL1-Ex40-rev: 5&#x02032;-TGCTTCCTCGGAAGTTCAAAGT. The refined analysis of transcript levels across tissue was performed using qPCR on the same samples and protocol for cDNA synthesis. Each cDNA was tested with a custom Taqman probe for detection of <italic>SORL1-38b</italic> (SORLA_EX_37-38B, AssayID AJBJXYH, Cat N. 4441114) (Applied Biosystems), and pre-designed probes for <italic>SORL1 exon 3&#x02013;4</italic> (Hs00268342_m1). Three household genes were analysed: <italic>HPRT1</italic> (Hs02800695_m1), <italic>TFRC</italic> (Hs00951083_m1), and <italic>TXNL1</italic> (Hs00355488_m1). Singleplex PCR was performed in 96-well plates LightCycler 480 System (Roche) with the following conditions: 95&#x000a0;&#x000b0;C for 10&#x000a0;s, 45 cycles of amplification (95&#x000a0;&#x000b0;C for 10&#x000a0;s, 60&#x000a0;&#x000b0;C for 30&#x000a0;s, 72&#x000a0;&#x000b0;C for 1&#x000a0;s), and 72&#x000a0;&#x000b0;C for 1&#x000a0;s. The efficiency and dynamic range for each qPCR assay was established using a serial dilution, and confirmed to be above 92% for all assays.</p></sec><sec id="Sec5"><title>Generation of <italic>SORL1-38b</italic> expression construct</title><p id="Par12">The small fragment in human <italic>SORL1</italic> from exon 37 to exon 38B was synthesized in pEX-A2 vector (MWG, Eurofins, Germany) including the native NdeI site in exon 37 and a NsiI site at the 3&#x02032; end. The fragment was cloned using NdeI and NsiI into the human <italic>SORL1</italic> in pGEM EASY vector [<xref ref-type="bibr" rid="CR19">19</xref>], and was subsequently subcloned to a pcDNA3.1 (Zeo) vector for cell studies. Site directed mutagenesis was used for introducing mutations leading to Cys to Ala substitutions at position 1 and 13 of the tail encoded by E38b using Quickchange XL Site-Directed Mutagenesis (Cat N. 200516) (Agilent). The same approach was applied for introducing stop codons after each 3Fn domain in a pcDNA3.1 plasmid containing the cDNA for human <italic>SORL1</italic>.</p></sec><sec id="Sec6"><title>Antibodies</title><p id="Par13">A polyclonal antibody against SORLA-38b was generated in rabbit by peptide immunization against the unique c-terminal VCFKTLTTHTKKGCWKSNQIHVP encoded by E38b (Aldevron, Germany). The immunogen CFKTLTTHTKKG-Abu-WKSNQIHVP was synthesized, where the C-terminal cysteine was substituted with aminobutyric acid (Abu). Keyhole limpet hemocyanin was conjugated to the immunogen for immunization. The antibody was subsequently purified from serum, and its specificity was assessed by Western blot (WB) analysis.</p><p id="Par14">Mouse monoclonal LR11 antibody was purchased from R&#x00026;D systems (Cat N. 611860), and rabbit polyclonal anti-sol SORLA (IgG 5387) and anti-tail SORLA were from colleagues at Aarhus University.</p></sec><sec id="Sec7"><title>Cell culture</title><p id="Par15">HEK-293 cells were cultured in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM, Sigma) supplemented with 10% fetal bovine serum and penicillin/streptomycin (P/S) in a humidified 5% CO<sub>2</sub> incubator at 37&#x000a0;&#x000b0;C. Fugene 6 Transfection Reagent kit (Cat N. E2691, Promega) was used to transfect cells with <italic>SORL1-38b</italic> or <italic>SORL1-fl</italic> constructs according to manufacturer&#x02019;s instructions. After 24&#x000a0;h, medium with zeocin was added to the transfected cells for selection and generation of a stable cell line expressing <italic>SORL1-38b</italic> construct. CHO cells were cultured in HyClone medium (Sigma) supplemented with 5% P/S, and were transfected with <italic>SORL1</italic> constructs using Fugene kit.</p></sec><sec id="Sec8"><title>Pulse-chase analysis</title><p id="Par16">Cells were incubated in methionine- and cysteine-free medium (Cat N. D0422, Sigma) supplemented with glutamax and 2% dialyzed FBS (Gibco) for 15&#x000a0;min at 37&#x000a0;&#x000b0;C, prior to biolabeling with [<sup>35</sup>S] Promix (Amersham Biosciences) for 40&#x000a0;min at 37&#x000a0;&#x000b0;C. Subsequently, cells were washed with phosphate-buffered saline (PBS), and both media and lysates were collected at different chase points. Cell lysates were immunoprecipitated at 4&#x000a0;&#x000b0;C overnight with GammaBind G-Sepharose beads (Amersham Biosciences) previously labeled with anti-sol-SorLA diluted in HyClone medium. Beads were then washed with PBS and proteins were resolved by standard SDS-PAGE and fluorography.</p></sec><sec id="Sec9"><title>Immunoblotting</title><p id="Par17">Transfected cells were lysed in lysis buffer containing protease inhibitor (Complete, Roche), and media were collected. Proteins were fractioned by 4&#x02013;12% SDS-gel electrophoresis, and transferred to nitrocellulose membranes (Amersham). Membranes were blocked in blocking buffer (20% TST buffer (0.25&#x000a0;M Tris-Base, 2.5&#x000a0;M NaCl, 0.5% Tween 20 pH 9), 2% skimmed milk powder, 2% Tween 20) for 1&#x000a0;h at RT, and incubated at 4&#x000a0;&#x000b0;C overnight with mouse anti-LR11 (1:500), and rabbit pAb-38b (1:1000) primary antibodies. Incubation with HRP-conjugated anti-mouse (1:1500) or anti-rabbit (1:1500) secondary antibodies was performed at RT for 1&#x000a0;h. Proteins were detected with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher) and visualized with LAS-1000 (GE Healthcare).</p></sec><sec id="Sec10"><title>In situ hybridization</title><p id="Par18">From NBB, paraffin embedded human cerebellum, hippocampus and entorhinal cortex were cut to 5&#x000a0;&#x003bc;m thick sections using a microtome. ISH was carried out by the BaseScope and BaseScope Duplex technologies (Advanced Cell Diagnostics) following manufacturer&#x02019;s instructions. Tissue hybridization was performed for 2&#x000a0;h at 40&#x000a0;&#x000b0;C (Hybez oven, ACDbio) with specific probes designed to span exon-exon junctions for recognition of <italic>SORL1-38b</italic> (E38E38b; E38bE39; E38bE40) and <italic>SORL1-fl</italic> transcripts (E38E39). In parallel, sections were hybridized with a PPIB probe (Cat N. 322975, ACDBio) as positive control. Chromogenic detection of specific hybridization was assessed with Fast Red dye (Cat N. 323600, ACDbio), and Fast Red-Green (Cat N. 323800, ACDBio). Nuclei counterstaining was made by incubation with Mayer&#x02019;s hematoxylin for 2&#x000a0;min at RT. Tissues were rinsed in deionized water and mounted with VectaMount permanent medium (Vector labs, Burlingame, CA). Slices were imaged with a Zeiss Apotome brightfield camera (Zeiss Apotome). Number of transcripts was manually quantified by counting punctate dots observed in PCs in the entire sections. Data were then plotted as mean number of transcripts per counting group (Group 0: 0 signal; Group I: 1 signal; Group II: 2&#x02013;3 signals; Group III:&#x02009;&#x0003e;&#x02009;4 signals). For quantification of somatic and extra-somatic transcripts after BaseScope treatment, 25 random fields were chosen at 20X magnification, counting three PCs in each field in order to compare homogenous tissue areas.</p></sec><sec id="Sec11"><title>RNA-seq read alignment</title><p id="Par19">Two published datasets were queried for the presence of RNA-seq reads spanning the exon 38b splice junctions. We downloaded RNA sequencing alignment files generated from the cerebellum [<xref ref-type="bibr" rid="CR33">33</xref>] along with frontal lobe, superior temporal gyrus and parahippocampal gyrus brain regions generated from the Mount Sinai Brain Bank [<xref ref-type="bibr" rid="CR46">46</xref>]. We quantified the ratio of E38E38b versus E38E39 splice junctions reads. Reads spanning the E38E38b, E38bE39 and E38bE40 junctions collected from parahippocampal gyrus samples were overlaid onto the UCSC human genome browser.</p></sec><sec id="Sec12"><title><italic>SORL1-38b</italic> differential expression in AD and non-AD samples</title><p id="Par20">The cDNA synthesis and qPCR analysis on the Mayo samples were conducted at Mayo Clinic. RNA was isolated from 50 cerebellum samples from the Mayo Clinic brain bank using TRIzol Reagent (Ambion Life Technology) followed by DNase RNA cleanup step using RNeasy (Qiagen). The quantity and quality of RNA samples were determined by the Agilent 2100 Bioanalyzer using Agilent RNA 6000 Nano Chip. All samples had an RNA integrity number (RIN) of&#x02009;&#x02265;&#x02009;6.6, with an equivalent mean RIN for both diagnosis groups (mean RIN AD&#x02009;=&#x02009;8.26, mean RIN controls&#x02009;=&#x02009;8.24). cDNA synthesis was performed with 1&#x02013;2&#x000a0;&#x003bc;g of RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems cat. no. 4387406) according to the manufacturer&#x02019;s instructions. The samples were tested with a custom Taqman probe for detection of <italic>SORL1-38b</italic>, and three housekeeping genes: <italic>HPRT1</italic>, <italic>TFRC</italic>, and <italic>TXNL1</italic>. Four replicate measures were taken per sample for each of the four Taqman assays (16 measures per sample) on 384 well reaction plates using the QuantStudio&#x02122; 7 Flex Real-Time PCR system and analysis software (Applied Biosystems, California, USA).</p><p id="Par21">The cDNA synthesis and qPCR analysis on the UW samples were conducted at the University of Washington. From each sample, 1&#x000a0;&#x003bc;g total cerebellum RNA was converted to cDNA (iScript, Biorad). SYBR Green qPCR was performed using Real-Time PCR Detection System (Biorad) with the following primers for <italic>SORL1-38b</italic>: E38b-Fw: 5&#x02032;-GCGGTGACTAGTCGTGGAAT and E38b-Rev: 5&#x02032;-TGCTCTTCCAACATCCCTTC. PCR products were amplified with the following conditions: 50&#x000a0;&#x000b0;C for 2&#x000a0;min, 95&#x000a0;&#x000b0;C for 20&#x000a0;s, 40 cycles of amplification (95&#x000a0;&#x000b0;C for 3&#x000a0;s, 60&#x000a0;&#x000b0;C for 30&#x000a0;s). Three housekeeping genes were used as controls: <italic>HPRT1</italic>, <italic>CYC1</italic> and <italic>RPL13</italic>.</p><p id="Par22">Each sample was run in triplicates, and water was included as negative control.</p></sec><sec id="Sec13"><title>Genotyping of SNP24</title><p id="Par23">Briefly, genomic DNA was prepared from cerebella samples from UW Neuropathology Core. DNA was genotyped for the presence of risk (T) or protective (C) allele at position rs2282649 by Sanger Sequencing (Genewiz). In total, 67 samples were genotyped and we observed 7&#x000a0;T/T carriers (10.4%), 29 C/C carriers (43.3%), and 31 C/T carriers (46.3%). To obtain groups of equal sample size, we chose 7 samples of each genotype (C/C, C/T, and TT) for 38b transcript analysis. One sample from the T/T genotype group failed qPCR of <italic>SORL1-38b</italic> due to Ct values outside the dynamic range for the assay. Primers for PCR of amplicon containing SNP24 was FW: 5&#x02032;-CTTTAGCTCATTCAGTATTCTTACTGTATG, and Rev: 5&#x02032;-GAGCATTTCTTCTAATGCAGACATAC.</p></sec><sec id="Sec14"><title>Statistical analysis</title><sec id="Sec15"><title>In situ semi quantitative analysis</title><p id="Par24">An unpaired student's t test was performed in Graphpad Prism 5.0 to compare differences and determine statistical significance between AD and non-AD samples. A <italic>p</italic> value below 0.05 was considered significant, indicated as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 (*), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 (**), and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 (***).</p></sec><sec id="Sec16"><title>Differential expression of 38b transcript in AD versus non-AD</title><p id="Par25">Comparison of normalized <italic>SORL1-38b</italic> transcript levels between AD and non-AD samples in the Mayo and UW cohorts was performed in R version 3.6.1. First, a linear regression between deltaCT and diagnosis was performed, with RIN (only available for Mayo cohort), age at death, gender and plate ID as covariates. As no significant association was found for any of the covariates, a Wilcoxon rank sum test was subsequently used to compare AD versus non-AD samples. A meta-analysis of the two cohorts was performed using the metap R package (version 1.3). (Dewey M (2020). metap: meta-analysis of significance values<italic>).</italic></p></sec><sec id="Sec17"><title>Association of SNP24 with AD</title><p id="Par26">Comparison of the risk allele frequency between AD and non-AD samples for SNP24 in the Mayo cohort was performed using Fisher&#x02019;s exact test. This test was not performed in the UW cohort, as samples were chosen based on genotype, so allele frequencies were not representative for AD cases and controls.</p></sec><sec id="Sec18"><title>Expression of 38b transcript stratified on SNP genotype</title><p id="Par27">Whole genome-sequence data for 35 of the Mayo Clinic samples is available via the AD Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org">https://adknowledgeportal.synapse.org</ext-link>, 10.7303/syn2580853). The AD Knowledge Portal is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to enable open-science practices and accelerate translational learning. The data, analyses and tools are shared early in the research cycle without a publication embargo on secondary use. Data is available for general research use according to the following requirements for data access and data attribution (<ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org/DataAccess/Instructions">https://adknowledgeportal.synapse.org/DataAccess/Instructions</ext-link>). For access to content described in this manuscript see: <ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/#!Synapse:syn11714444">https://www.synapse.org/#!Synapse:syn11714444</ext-link>. Genotypes were extracted from the available VCF files using vcftools version 0.1.17.</p><p id="Par28">To determine the effect of SNP24 on transcript levels, type I ANOVA was used to compare the three groups, C/C, C/T and T/T, with diagnosis as covariate. Normal distribution was checked visually using qqplot and Shapiro&#x02013;Wilk test. The eQTL analysis of 38b was performed on 35 samples from the Mayo cohort using the MatrixEQTL package [<xref ref-type="bibr" rid="CR41">41</xref>]. The cis-eQTL analysis was restricted to SNPs in the <italic>SORL1</italic> gene&#x02009;&#x000b1;&#x02009;1 Mbp. Only SNPs with at least 5 and at most 65 alternate allele counts of the total 70 alleles were used. MatrixEQTL was run with modelLINEAR and disease status as covariate.</p></sec></sec></sec><sec id="Sec19"><title>Results</title><sec id="Sec20"><title>Identification of a novel primate-specific exon in SORL1</title><p id="Par29">The <italic>SORL1</italic> gene on human chromosome 11 spans&#x02009;&#x0003e;&#x02009;181&#x000a0;kb and contains at least 48 assigned exons [<xref ref-type="bibr" rid="CR36">36</xref>]. The mRNA produced by assembling these known exons encodes the main form of SORLA referred to as the full-length receptor (SORLA-fl).</p><p id="Par30">Here we validated the existence of a novel 118&#x000a0;bp exon located between exons 38 and 39, hereafter referred to as &#x0201c;exon 38b&#x0201d; (E38b) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). A human tissue RNA library was screened by RT-PCR using an E38b specific primer pair (for exons 35/38b), revealing inclusion of this exon in transcripts from numerous tissues, including both fetal and adult brain. Several tissues did not express <italic>SORL1-38b</italic> although they were positive for canonical <italic>SORL1</italic> transcripts (identified by primer pair for exons 2/3), indicating differential expression of the alternatively spliced transcript (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b).<fig id="Fig1"><label>Fig. 1</label><caption><p>A novel alternatively spliced <italic>SORL1</italic> transcript encodes a truncated receptor. <bold>a</bold> Schematic representation of the genomic region of <italic>SORL1</italic> including the novel exon 38b (red) located in close proximity to SNP24 within the 3&#x02032; risk haplotype (~&#x02009;1200&#x000a0;bp). Primers for amplification of the 388&#x000a0;bp fragment between exon 35 and 38b are indicated with arrows. <bold>b</bold> RT-PCR showing specific expression of <italic>SORL1-38b</italic> transcripts (E35&#x02013;E38b) in only some human tissues, compared to ubiquitous expression of <italic>SORL1</italic> transcripts containing exons 2 and 3 (E2&#x02013;E3), and 18S ribosomal RNA (RN18S) as control. <bold>c</bold> WB analysis of lysates and media of cells transfected with cDNA encoding either SORLA-fl or SORLA-38b. The antibody pAb-38b specifically recognizes the truncated 188&#x000a0;kDa SORLA-38b receptor, but not the SORLA-fl protein (250&#x000a0;kDa). <bold>d</bold> [<sup>35</sup>S]-pulse-chase analysis on cells transfected with constructs encoding SORLA-fl (left) or SORLA-38b (right), with both isoforms mainly located in cell lysates. SORLA-fl goes from an immature (black arrowhead) to a mature (white arrowhead) form during the 8&#x000a0;h chase period, and the mature protein can be shed into the medium after 4&#x000a0;h. Trace amounts of SORLA-38b is secreted as early as 30&#x000a0;min after radiolabeling, but can undergo endocytosis and be re-secreted in a mature form after 4&#x000a0;h. <bold>e</bold> WB analysis for a panel of SORLA deletion constructs terminating after different 3Fn-domains in cell lysates (L) or medium (M), showing how the presence of the fifth 3Fn-domain (3Fn5) is responsible for cellular retention of soluble SORLA constructs. <bold>f</bold> Genomic sequence of E38b (in red) with flanking splice regions (in black), including translated amino acid sequence shown on top</p></caption><graphic xlink:href="40478_2021_1140_Fig1_HTML" id="MO1"/></fig></p><p id="Par31">Sequencing of the RT-PCR product from brain identified a E38b-containing transcript encoding a protein with 22 new amino acids followed by a stop-codon (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>f). The resulting truncated receptor protein is hereafter termed SORLA-38b (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Notably, the junction between exons 38 and 39 corresponds exactly to the boundary between the second and the third fibronectin-type III (3Fn)-domains of SORLA (between residues 1747 and 1748). Alignment analysis of the genomic sequence across species confirmed E38b conservation from human to <italic>Pan Troglodytes</italic>, <italic>Macaca mulatta</italic>, and <italic>Gorilla gorilla</italic> genomes, whereas this exonic cassette is absent in non-primate phylogeny.</p><p id="Par32">The presence of the unique 22 residues allowed us to raise an antibody (pAb-38b, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c, d) specifically recognizing the unique C-terminal end of SORLA-38b, thereby enabling us to distinguish the truncated isoform from SORLA-fl, as demonstrated by WB analysis. As expected, only cells transfected with a cDNA for <italic>SORL1-38b</italic>, but not <italic>SORL1-fl</italic>, produced a product recognized by pAb-38b. Surprisingly, in this experiment only a limited fraction of SORLA-38b was secreted into the medium despite the lack of any transmembrane region, suggesting another mechanism of cell retention (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). A [<sup>35</sup>S]-pulse-chase experiment confirmed that SORLA-38b stays mainly cell-associated (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d).</p><p id="Par33">To investigate why SORLA-38b is not efficiently secreted, we experimentally substituted each of two cysteine residues that are present in the unique SORLA-38b sequence. We found that neither of the two residues&#x02014;when mutated separately or simultaneously&#x02014;had any effect on secretion (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1a). As deletion of all 22 amino acids from the SORLA-38b isoform also did not affect secretion, we finally measured secretion of a panel of SORLA deletion constructs, demonstrating that the presence of the fifth 3Fn-domain is essential for secretion of the SORLA extracellular domain (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1b). Although the exact molecular mechanism remains to be determined in detail, these data strongly suggest that the truncated SORLA-38b is structurally different compared to the full-length SORLA receptor, in line with distinct unrelated functions.</p><p id="Par34">Combined, these findings indicate tissue-specific expression of a novel <italic>SORL1</italic> transcript, that can be translated into a truncated and stable SORLA-38b protein isoform with a function unrelated to the full-length receptor.</p></sec><sec id="Sec21"><title>High SORL1-38b expression in cerebellum</title><p id="Par35">We next measured the expression levels of <italic>SORL1-38b</italic> across multiple brain regions by RT-PCR. While expression was evident for all tested regions including the temporal lobe, hippocampus, frontal cortex and entorhinal cortex, a consistently higher expression was observed in the cerebellum, a region previously reported to express high levels of SORLA [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. A follow-up qPCR analysis demonstrated 2.1-fold enrichment of <italic>SORL1-38b</italic> transcript in cerebellum compared to whole brain (i.e. &#x00394;&#x00394;Ct&#x02009;=&#x02009;&#x02212;&#x02009;1.1) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b). Accordingly, we focused our first analysis on cerebellum.<fig id="Fig2"><label>Fig. 2</label><caption><p><italic>SORL1-38b</italic> is expressed in cerebellar Purkinje cells. <bold>a</bold> RT-PCR analysis showing expression of <italic>SORL1-38b</italic> (primers E35&#x02013;E38b) and control <italic>SORL1</italic> transcripts (primers E2&#x02013;E3) in brain regions. <bold>b</bold> qPCR analysis of <italic>SORL1-38b</italic> expression in human brain regions relative to housekeeping genes <italic>HPRT1</italic>, <italic>TFRC</italic> and <italic>TXNL1</italic>. Data are depicted as fold change relative to expression in total brain. <italic>Cer</italic> cerebellum, <italic>Front cortex</italic> frontal cortex, <italic>Hip</italic> hippocampus, <italic>Temp lobe</italic> temporal lobe. <bold>c</bold> Schematic representation showing how custom-designed BaseScope double-Z probes target the junctions between exon 38 and 38b (E38E38b), and between exon 38 and 39 (E38E39) to specifically detect E38b-containing transcripts. <bold>d</bold> BaseScope analysis using E38E38b probe confirms the presence of exon 38b-containing transcripts in human cerebellum. <italic>PC</italic> Purkinje cells, <italic>GC</italic> granule cells. Scale bar, 20&#x000a0;&#x003bc;m. <bold>e</bold> BaseScope images showing that E38E39 probe is mainly localized in the soma of PCs (bottom panel), whereas E38E38b probe signal is found in the soma but also distributed in the dendrites of PCs (top panel). Scale bar, 50&#x000a0;&#x003bc;m. <bold>f</bold> Quantification of the number of <italic>SORL1-38b</italic> (E38E38b) and <italic>SORL1-fl</italic> (E38E39) transcripts localized in the dendrites of PCs. Individual data points represent quantification from 3 independent brains, and in each section&#x000a0;25 random pictures showing homologous cerebellum regions were used for the analysis (n&#x02009;=&#x02009;225 cells/probe). ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="40478_2021_1140_Fig2_HTML" id="MO2"/></fig></p><p id="Par36">To determine in detail the histological distribution of <italic>SORL1-38b</italic> transcript, we employed BaseScope technology for the in&#x000a0;situ detection of the splice variant and <italic>SORL1-fl</italic> in brain specimens (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). Whereas the probe for <italic>SORL1-fl</italic> evenly labelled all Purkinje cells (PCs) as well as many cells in the granule cell layer (GCL), the probe for <italic>SORL1-38b</italic> showed a restricted signal mainly within the Purkinje cell layer and clearly absent from the GCL (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). Detailed inspection of the cerebellar sections tested for <italic>SORL1</italic> expression revealed a difference in the cellular distribution of the two probes (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). While the signal for <italic>SORL1-fl</italic> was predominantly (89%) located in the soma of PCs, <italic>SORL1-38b</italic> was only partially present in the PC soma (46%) with the majority of labelled transcripts located in the molecular layer where the dendritic tree of PCs extends (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>e, f).</p><p id="Par37">These results pointed out PCs as the major source of production of E38b-containing <italic>SORL1</italic> transcripts in the cerebellum, and showed a regional difference between transcripts encoding SORLA-fl and SORLA-38b.</p></sec><sec id="Sec22"><title>Exon 38b determines neuronal dendritic targeting</title><p id="Par38">As the 3&#x02032; UTR of transcripts is often involved in mRNA transportation in neurons [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], we next applied a protocol for analyzing the 3&#x02032; end of the transcript by 3&#x02032; RACE PCR using RNA from human cerebellum. We found that both <italic>SORL1-38b</italic> and <italic>SORL1-fl</italic> end with exon 48 suggesting identical poly-adenylation for the two isoforms (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2). We further examined the immediate 3&#x02032; region downstream of the stop-codon (introduced by inclusion of E38b) by RT-PCR using RNA from four different brain regions as well as whole brain. This analysis demonstrated the presence of two distinct E38b-containing transcripts, most notably in the cerebellum (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). Sequencing of these two PCR products identified a second alternative splice event where E38b can join directly to either the downstream exon 39 or to exon 40 by exclusion of exon 39.<fig id="Fig3"><label>Fig. 3</label><caption><p>Alternative splicing of exon 38b determines soma-dendritic transport of <italic>SORL1</italic> transcripts. <bold>a</bold> RT-PCR using primers in exon 38b and 40 (E38b&#x02013;E40) revealed the presence of the additional splicing event with skipping of exon 39 downstream the novel 38b cassette. <bold>b</bold> Schematic of BaseScope probe design for targeting <italic>SORL1-38b</italic> transcripts containing (E38bE39, blue) or excluding exon 39 (E38bE40, red). <bold>c</bold> Representative image of BaseScope Duplex using the probes E38bE39 (blue) and E38bE40 (red) shows that exon 39 is not responsible for soma retention. Scale bar, 20&#x000a0;&#x003bc;m. <bold>d</bold> Junction-spanning reads in human brain regions confirm the existence of two <italic>SORL1-38b</italic> transcripts from inclusion or exclusion of exon 39. Numbers represent the relative frequency of <italic>SORL1-38b</italic> reads among all <italic>SORL1</italic> reads (%). <bold>e</bold> BaseScope analysis using probes E38E38b and E38E39 shows the presence of extra-somatic <italic>SORL1-38b</italic> transcripts in different human brain areas. Signals for E38E39 that represent <italic>SORL1-fl</italic> are predominantly located in the neuronal soma. <italic>Ento ctx</italic> entorhinal cortex, <italic>Hip</italic> hippocampus, <italic>DG</italic> dentate gyrus. Scale bar, 50&#x000a0;&#x003bc;m. <bold>f</bold> Immunostaining of human cerebellum with an antibody raised against the cytoplasmic tail (SORLA-cyt) of SORLA-fl reveals that the full-length protein is mainly located to the soma of PCs. Staining with antibodies against the luminal part of SORLA (SORLA-lum; LR11, 5387) shows labeling of soma as well as dendrites of PCs (indicated with arrowheads)</p></caption><graphic xlink:href="40478_2021_1140_Fig3_HTML" id="MO3"/></fig></p><p id="Par39">Because transcripts for <italic>SORL1-fl</italic> contain exon 39 and mainly locate to the neuronal soma, we hypothesized a model where exon 39 would dictate somatic retention, and consequently account for the observed distribution of <italic>SORL1-38b</italic> transcripts split between soma and dendrites. A similar role for specific exons of BDNF mRNA has previously been demonstrated, showing how individual exons contain motifs responsible for soma retention or dendritic transport [<xref ref-type="bibr" rid="CR3">3</xref>]. To investigate this, we designed two probes for BaseScope detection of <italic>SORL1-38b</italic> either including exon 39 (E38bE39) or skipping exon 39 (E38bE40) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). We then applied the BaseScope Duplex assay for simultaneous visualization of both probes on the same cerebellum sample. In this experiment both probes gave signals within PC dendritic trees (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c), indicating that skipping of exon 39 is not related to somatic localization of <italic>SORL1-38b</italic> transcripts, and suggesting that inclusion of E38b drives <italic>SORL1</italic> mRNA into dendrites.</p><p id="Par40">Next, we analysed a number of human brain tissue RNA-seq datasets from available data repositories. By this approach we not only provide further evidence for the presence of <italic>SORL1-38b</italic> transcripts in all investigated samples, but also confirmed that skipping of exon 39 in the presence of E38b can occur in neurons in various brain regions, including the frontal lobe, hippocampal formations, and superior temporal gyrus (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). In agreement with our experimental findings, the highest number of <italic>SORL1-38b</italic> transcripts was observed for cerebellum, where it accounts for&#x02009;~&#x02009;0.6% of all <italic>SORL1</italic> reads.</p><p id="Par41">In situ analyses using probes E38E38b and E38E39 on human entorhinal cortex and hippocampal areas CA4 and dentate gyrus (DG) not only validated the expression of <italic>SORL1-38b</italic>, but also confirmed how most E38b-transcripts are located at the dendritic part of neurons opposed to somatic localization of <italic>SORL1-fl</italic> (positive for E38E39) in these brain regions (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e).</p><p id="Par42">We did several attempts to detect SORLA-38b expression in dendrites of cerebellar sections using our pAb-38b antibody. While we were able to see signal in PC soma and dendrites using this antibody (in line with the presence of <italic>SORL1-38b transcripts)</italic>, we experienced trouble with a background signal in the GCL that confounded the data. We therefore took an alternative approach to support a difference in cellular localization between truncated and SORLA-fl isoforms. Using an antibody that binds the cytoplasmic tail of SORLA, we found that SORLA-fl is almost exclusively located in the PC soma, whereas two different antibodies (IgGs LR11 and 5387), binding to epitopes in the extracellular receptor domain and therefore unable to distinguish between SORLA-fl and SORLA-38b, gave an additional strong signal in the dendritic tree of PCs that was only rarely seen in pictures from immunostainings using the tail antibody (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>f).</p><p id="Par43">Together, our findings indicate that the <italic>SORL1-38b</italic> splice variant has a pronounced dendritic localization, likely underlining a yet undefined function. Further studies are necessary to elucidate the molecular drivers as well as the physiological conditions responsible for this dendritic targeting.</p></sec><sec id="Sec23"><title>The SORL1-38b transcript is downregulated in AD cerebellum</title><p id="Par44">The cerebellum is historically considered a region of the brain showing little vulnerability for AD [<xref ref-type="bibr" rid="CR6">6</xref>], although recent studies also link cerebellum to cognitive decline [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Robust SORLA expression in cerebellum in AD has previously been observed [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR30">30</xref>,&#x000a0;<xref ref-type="bibr" rid="CR38">38</xref>] despite decreased levels in disease-affected regions including frontal cortex and hippocampus [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, these previous studies did not take into account that alternative isoforms of <italic>SORL1</italic> may be altered. As dendritic and synaptic connectivity loss is one of the driving events occurring in AD, we next asked if <italic>SORL1-38b</italic> levels are affected in the cerebellum of AD patients.</p><p id="Par45">As expected, tissue sections from cerebellum of AD and non-AD individuals showed no gross abnormalities despite disease status. To ensure comparable RNA quality between AD and non-AD samples, we hybridized the cerebellar sections with a probe targeting the human <italic>PPIB</italic> gene, indicating no general RNA decay in these cerebellar AD samples (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Fig. S3). We next performed a quantitative analysis of the expression of <italic>SORL1-38b</italic> transcripts in PC soma by BaseScope assay by applying probe E38E38b to tissue sections from 3 AD and 3 non-AD individuals (sample data listed in Table <xref rid="Tab1" ref-type="table">1</xref>), and quantified the levels of transcripts. As indication of the expression level, we could group the PCs according to the copy number of E38b-containing transcripts expressed by PCs, and we classified into four groups according to the signal detected per cell soma (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). Surprisingly, we observed a markedly reduced expression of the <italic>SORL1-38b</italic> isoform in all three AD samples (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b).<fig id="Fig4"><label>Fig. 4</label><caption><p>Reduced expression of the alternatively spliced <italic>SORL1-38b</italic> transcript in cerebellum of AD patients. <bold>a</bold> Representative images of ISH in human cerebella from non-AD individuals using E38E38b probe for detection of <italic>SORL1-38b</italic> transcripts. Cells were grouped in 4 different groups according to copy-number of mRNAs: group 0 (0 signals), group I (1 signal), group II (2&#x02013;3 signals), and group III (&#x0003e;&#x02009;4 signals). Scale bar, 50&#x000a0;&#x003bc;m. <bold>b</bold> Quantification of BaseScope signal in groups of PCs with E38E38b probe confirms significant reduction of <italic>SORL1-38b</italic> transcripts in the cerebellum from AD patients (N&#x02009;=&#x02009;3, n&#x02009;=&#x02009;1006; non-AD; N&#x02009;=&#x02009;3, n&#x02009;=&#x02009;1444). Scale bar, 20&#x000a0;&#x003bc;m. *<italic>p</italic>&#x0003c;0.05,&#x000a0;**<italic>p</italic>&#x0003c;0.01, ***<italic>p</italic>&#x0003c;0.001.&#x000a0;<bold>c</bold> Quantification of BaseScope readouts indicates no significant differences of E38E39 probe signal in AD cerebella compared to non-AD controls (non-AD, N&#x02009;=&#x02009;3, n&#x02009;=&#x02009;2936 cells in total; AD; N&#x02009;=&#x02009;3, n&#x02009;=&#x02009;2768 cells in total). Scale bar, 20&#x000a0;&#x003bc;m. <bold>d</bold> Representative images of ISH signal using E38E39 probe show that <italic>SORL1-fl</italic> is similarly expressed in GCs in non-AD and AD cerebella. Scale bar, 50&#x000a0;&#x003bc;m</p></caption><graphic xlink:href="40478_2021_1140_Fig4_HTML" id="MO4"/></fig></p><p id="Par46">Detailed quantification based on the signal in the soma revealed that 46.6% of all measured PCs (n&#x02009;=&#x02009;1444) were negative (group 0) by the E38E38b ISH analysis in non-AD cerebella, and the remaining 53.4% positive PCs distributed equally between groups I-II-III (19.7% group I; 20.5% group II; 13.2% group III). However, in cerebella from AD patients, 93.0% of all PCs showed a lack of <italic>SORL1-38b</italic> expression (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 compared to non-AD distribution in group 0), accompanied by a significant reduction in the number of PCs corresponding to groups I (5.5%; <italic>p</italic>&#x02009;=&#x02009;0.0177) and II (1.5%; <italic>p</italic>&#x02009;=&#x02009;0.0002) with no cells assigned to group III (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b).</p><p id="Par47">In parallel, we tested the same brains to detect <italic>SORL1-fl</italic> transcripts. In line with previous reports that showed robust SORLA expression in AD cerebellum [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], we did also not see any difference for <italic>SORL1-fl</italic> levels between AD and non-demented controls (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). Quantification of the hybridization signal for the E38E39 probe showed that the majority of PCs (67.3%) expresses high levels of <italic>SORL1-fl</italic> transcript (group III), and that none of the four groups were affected by AD (group 0, <italic>p</italic>&#x02009;=&#x02009;0.4197; group I, <italic>p</italic>&#x02009;=&#x02009;0.4674; group II, <italic>p</italic>&#x02009;=&#x02009;0.8955; group III, <italic>p</italic>&#x02009;=&#x02009;0.5474) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). Similarly, we did not observe any decrease in the signal for <italic>SORL1-fl</italic> in the GCL (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). These findings confirmed <italic>SORL1-fl</italic> is abundantly and robustly expressed in the human cerebellum, and its expression is not affected by AD in this brain region.</p></sec><sec id="Sec24"><title>Replication analysis of transcript levels</title><p id="Par48">To replicate the finding of lowered <italic>SORL1-38b</italic> expression in brains from AD patients, we used Taqman qPCR to quantify <italic>SORL1-38b</italic> levels in AD versus non-AD brains in two additional independent cohorts. First, we investigated 25 AD and 25 non-AD post-mortem cerebella samples identifying a mean 2.0-fold down-regulation of <italic>SORL1-38b</italic> transcript levels in AD cerebellum compared to controls (<italic>p</italic>&#x02009;=&#x02009;0.0010) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Of notice, this cohort was previously analyzed and showed no reduction of <italic>SORL1-fl</italic> in AD patients compared to controls [<xref ref-type="bibr" rid="CR5">5</xref>], demonstrating again that the two <italic>SORL1</italic> isoforms are differently affected by AD. Consistent with this, a qPCR analysis of 14 AD and 6 non-AD cerebella samples identified a mean 2.4-fold down-regulation of <italic>SORL1-38b</italic> transcripts in AD brains compared to non-AD brains (<italic>p</italic>&#x02009;=&#x02009;0.076) and no change in <italic>SORL1-fl</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). Quantification of the PC marker Calbindin relative to the reference genes showed no differences between AD and non-AD samples from the UW cohort (&#x00394;&#x00394;Ct&#x02009;=&#x02009;&#x02212;&#x02009;0.08; <italic>p</italic>&#x02009;=&#x02009;0.869). A meta analysis of the two cohorts (in total 39 AD; 31 non-AD) found a mean 2.1-fold decrease of <italic>SORL1-38b</italic> in AD (p<sub>meta</sub>&#x02009;=&#x02009;0.00035) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c).<fig id="Fig5"><label>Fig. 5</label><caption><p>Meta-analysis of <italic>SORL1-38b</italic> expression in non-AD and AD cerebellum. <bold>a</bold> TaqMan qPCR assay using a probe designed for detection of <italic>SORL1-38b</italic> transcripts shows a 2.0-fold reduction in expression levels in AD cerebellum compared to non-AD controls from a Mayo Clinic cohort (non-AD; N&#x02009;=&#x02009;25, AD; N&#x02009;=&#x02009;25). <bold>b</bold> qPCR analysis on non-AD and AD cerebellum from UW cohort confirms reduction of <italic>SORL1-38b</italic> in AD samples (non-AD; N&#x02009;=&#x02009;6; AD; N&#x02009;=&#x02009;14). <bold>c</bold> Meta-analysis including expression levels of <italic>SORL1-38b</italic> in non-AD versus AD cerebella from Mayo Clinic and UW cohorts. <bold>d</bold>&#x02013;<bold>f</bold> Relative expression of <italic>SORL1-38b</italic> to the genotype of SNP24 located in the 3&#x02032; haplotype of <italic>SORL1</italic> (rs2282649) in Mayo Clinic (<bold>d</bold>; non-AD; N&#x02009;=&#x02009;23, AD; N&#x02009;=&#x02009;12), UW cohort (<bold>e</bold>; non-AD; N&#x02009;=&#x02009;6; AD; N&#x02009;=&#x02009;14), and meta-analysis including data from both cohorts (<bold>f</bold>)</p></caption><graphic xlink:href="40478_2021_1140_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec25"><title>Transcript levels stratified by SNP24</title><p id="Par49">The first association study focusing on <italic>SORL1</italic>, carried out by Rogaeva and coworkers in 2007 [<xref ref-type="bibr" rid="CR36">36</xref>], identified an association with AD for two different haplotypes in <italic>SORL1</italic>, more specifically a 5&#x02032; risk-haplotype and a 3&#x02032; risk-haplotype in the gene [<xref ref-type="bibr" rid="CR36">36</xref>]. While the association with 5&#x02032; risk-haplotype has been linked to reduced BDNF-induced <italic>SORL1</italic> activity [<xref ref-type="bibr" rid="CR49">49</xref>], the underlying reason for the 3&#x02032;risk haplotype association remains unclear. In 2019, a large GWAS of AD identified a single risk locus in <italic>SORL1</italic> with lead SNP rs11218343 [<xref ref-type="bibr" rid="CR20">20</xref>]. The locus spans around 68&#x000a0;kb (from rs7946599 to rs75439772) and includes E38b as well as the 3&#x02032; haplotype [<xref ref-type="bibr" rid="CR20">20</xref>] (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Fig. S4a). One of the SNPs tagging the 3&#x02032; haplotype is rs2282649, labelled SNP24 in the Rogaeva study [<xref ref-type="bibr" rid="CR36">36</xref>]. Because of the association previously reported and the genomic position of SNP24 close to E38b (around 1200&#x000a0;bp), we speculated if rs2282649/SNP24 was associated with AD, and if SNP24 genotypes correlated with <italic>SORL1-38b</italic> levels. Out of the 50 Mayo cerebellum samples, 35 samples had genotypes available for rs2282649/SNP24 from whole-genome sequencing in the AMP-AD knowledge portal. The samples from UW were genotyped for SNP24 and selected to enrich for individuals with the T/T genotype.</p><p id="Par50">In the Mayo subset (12 AD and 23 non-AD) the SNP24 allele frequency of the risk allele (T-allele) was higher among AD samples (41.7%) compared to non-AD samples (19.6%) (<italic>p</italic>&#x02009;=&#x02009;0.09), supporting a trend for association of this variant with AD in this small sample. Because samples from the UW cohort were selected for qPCR based on their SNP24 genotype, allele frequencies are not representative for AD cases and controls, and they were not included in the association analysis with disease status.</p><p id="Par51">Stratifying the Mayo and the UW samples according to SNP24 genotypes revealed a decreasing tendency in <italic>SORL1-38b</italic> levels in carriers of the risk genotype T/T of SNP24 (rs2282649) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d, e) (<italic>p</italic><sub><italic>meta</italic></sub>&#x02009;=&#x02009;0.14, analysis adjusted for AD status) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>f). To determine if SNP24 is a true eQTL for <italic>SORL1-38b</italic> levels, a larger number of samples is needed, with both genotypes <italic>and</italic> E38b transcript levels available.</p><p id="Par52">To test if any stronger eQTLs for 38b existed in the <italic>SORL1</italic> locus, genetic variants in <italic>SORL1</italic> as well as up- and downstream were downloaded from the AMP-AD knowledge portal for the 35 Mayo samples. Apart from a small cluster of SNPs in the <italic>SORL1</italic> promoter, which was to be expected, no other strong eQTL could be identified for E38b-transcript levels within the <italic>SORL1</italic> locus (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Fig. S4b). Future studies with a larger number of individuals, including also carriers of the GWAS index SNPs, could reveal if the mechanism underlying common-variant association of <italic>SORL1</italic> with AD involves the E38b transcript.</p></sec></sec><sec id="Sec26"><title>Discussion</title><p id="Par53">We have previously shown how a <italic>SORL1</italic> transcript that differs from full-length is generated by an alternative transcriptional start site [<xref ref-type="bibr" rid="CR5">5</xref>], but <italic>SORL1-38b</italic> is to our knowledge the first alternatively spliced isoform of the AD gene <italic>SORL1</italic> that has been documented. Interestingly, our findings showed that the inclusion of E38b in transcripts primes mRNA translocation targeting <italic>SORL1-38b</italic> to extra-somatic compartments in neurons. Such asymmetrical distribution of mRNA may be more thermodynamically efficient than transporting proteins as fewer mRNA molecules need to be mobilized [<xref ref-type="bibr" rid="CR8">8</xref>]. Neurons in particular rely on mRNA translocation as a mechanism to coordinate regional and temporal changes in protein levels in both axonal and dendritic compartments, as well as by local protein synthesis to affect synaptic plasticity of individual synapses [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par54">For our studies, we focused on the cerebellum showing the highest relative expression of <italic>SORL1-38b</italic>, like for <italic>SORL1-fl</italic>. Also, we confirmed both the expression of this isoform and its dendritic localization in neurons of hippocampus and cortical regions that are affected by AD. This suggests the cerebellum as a model system to study <italic>SORL1-38b</italic> biology, allowing the translation of our findings to other brain areas affected by AD pathology. The high cerebellar expression may reflect the fact that Purkinje neurons have the most elaborate dendritic trees among neurons in the brain [<xref ref-type="bibr" rid="CR42">42</xref>], with a huge number of dendritic spines that could be particularly dependent on <italic>SORL1</italic> splicing. The role of <italic>SORL1-38b</italic> is not clear, but it may act similarly to protocadherins where AS has been reported to influence self-avoidance of dendrites in cerebellar PC [<xref ref-type="bibr" rid="CR23">23</xref>]. Accordingly, <italic>SORL1-38b</italic> could play an important role to provide synapse and neuronal identity.</p><p id="Par55">Here, we provide evidence that <italic>SORL1-38b</italic> is decreased in the cerebellum of patients with AD, using samples from three independent cohorts. While <italic>SORL1-fl</italic> is not decreased in cerebellum of AD patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], we found a significant decrease of <italic>SORL1-38b</italic> in AD patients from all three cohorts. This is interesting as cerebellum, which is usually described as unaffected in AD, recently has gained attention as playing a role in cognitive decline&#x000a0;[<xref ref-type="bibr" rid="CR18">18</xref>], with evidence showing that network-based degeneration in AD extends to the cerebellum [<xref ref-type="bibr" rid="CR16">16</xref>]. Although AS has previously been studied in relation to AD [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], this is the first description of a <italic>SORL1</italic> isoform affected in the cerebellum of AD patients.</p><p id="Par56">The specific decrease of <italic>SORL1-38b</italic> levels in AD suggested a unique difference in either production or degradation between this isoform and <italic>SORL1-fl</italic>. An AD-dependent change of the splicing machinery necessary for E38b inclusion may explain differences in the production of the two isoforms. Alternatively, a decrease in the dendritic machinery responsible for transporting the mRNA or being related to previously reported synaptic and dendritic loss in AD including loss of synapses of PCs in AD [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] could explain the observed decrease. However, any mechanism where <italic>SORL1-38b</italic> loss is a consequence of its localization into dendrites/synapses would seem to require a feedback mechanism in order to additionally explain the observed decrease of <italic>SORL1-38b</italic> in the neuronal soma by ISH. Interestingly, the most severe reduction of <italic>SORL1-38b</italic> in AD cerebella was found in the NBB cohort, only including samples at advanced stages compared to UW and Mayo cohorts. This could reflect a positive correlation between severity of E38b-transcripts downregulation and stage of AD.</p><p id="Par57">If the identified reduction of E38b is a consequence of synaptic loss due to AD, our findings may also be relevant for other neurodegenerative disorders like Parkinson&#x02019;s disease and frontotemporal dementia. It would therefore be of interest for future studies to determine <italic>SORL1-38b</italic> levels also for non-AD degenerative diseases, as well as looking further into the possible association between <italic>SORL1-38b</italic> and SNP24 that is specifically reported to associate with AD [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par58">Translation of transcripts including E38b leads to production of a truncated SORLA isoform lacking four 3Fn-domains as well as transmembrane and cytoplasmic domains that are all present in SORLA-fl. This suggests different functions of the two isoforms, in line with multiple studies reporting that locally synthesized proteins are most often structurally and functionally distinct from proteins present at the same cellular site but being transported to their destination [<xref ref-type="bibr" rid="CR8">8</xref>]. Usually, transcripts containing a premature stop codon (PSC) are targets of the nonsense mediated decay (NMD) pathway. However, it has been previously shown that a human specific splice variant of the <italic>Survival Motor Neuron 1</italic> (<italic>SMN1</italic>) gene holding a PSC, after introduction of a novel exon, is able to escape NMD and be locally translated in neuronal terminals [<xref ref-type="bibr" rid="CR40">40</xref>]. Similarly, NMD degradation of <italic>SORL1-38b</italic> may be prevented by trafficking the transcript to dendrites where the truncated SORLA-38b protein is produced.</p><p id="Par59">SORLA-fl is known to regulate sorting of a number of cargo proteins including APP and the Amyloid-&#x003b2; peptide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], in a process that requires complex formation between the SORLA tail domain and cytosolic trafficking factors, most notably the retromer complex [<xref ref-type="bibr" rid="CR15">15</xref>]. This activity determines sorting of SORLA and its cargo in Golgi and endosomal compartments of the neuronal soma. Here, we were puzzled why SORLA-38b is not merely being secreted in the absence of the transmembrane anchor, as a construct encoding the longer extracellular region of SORLA containing all six 3Fn-domains become efficiently secreted [<xref ref-type="bibr" rid="CR39">39</xref>]. Our experiment to determine if the presence of the E38b-encoding 22 amino acids was responsible for this cellular retention showed that the E38b-encoded peptide was not responsible for the lack of secretion. Subsequent studies revealed that the ability to leave the cell is determined by the presence of the fifth 3Fn-domain in the SORLA ectodomain, likely reflecting conformational rearrangements of the SORLA extracellular part in the absence of this domain. This strongly support our hypothesis that SORLA-38b has its own cellular function unrelated to SORLA-fl.</p><p id="Par60">The exact function of the shorter SORLA-38b isoform is not clear, but it is very tempting to speculate a role related to synaptic plasticity, which is the most frequent function associated with localized protein synthesis in dendrites [<xref ref-type="bibr" rid="CR45">45</xref>]. The study of the function of SORLA-38b is complicated as it is not expressed in rodents. We attempted to differentiate neurons from human induced pluripotent stem cells, however the applied protocol previously shown to provide a model for studying the function of SORLA-fl [<xref ref-type="bibr" rid="CR22">22</xref>] unfortunately failed to induce sufficient levels of <italic>SORL1-38b</italic> expression (determined by qPCR; data not shown). This observation is in line with our present findings where only a subset of neurons expresses the alternatively spliced isoform. We suggest future studies should apply protocols for differentiation into PCs [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] to increase the possibility that the induced neurons will express sufficient SORLA-38b to allow for functional studies.</p><p id="Par61">SORLA has previously been speculated to act as an adhesion protein, because 3Fn-domains are often present in adhesion molecules, including protocadherins, immunoglobulin superfamily and contactins [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Interestingly, inclusion of an alternative exon in <italic>CNTN4</italic> (encoding Contactin-4) introduces a novel stop codon and generates a truncated protein with deletion of several 3Fn-domains [<xref ref-type="bibr" rid="CR50">50</xref>] similarly to what we here describe for SORLA-38b. Detection of the truncated form of Contactin-4 in human brain samples confirmed the production of a stable isoform. AS of proteins involved in cellular adhesion has been reported to generate extensive diversity for neuronal intercellular recognition, often in a cell type specific way. Such splice-dependent interactions play fundamental roles in neural circuit establishment and maintenance, including repulsion and attraction allowing neurites to form specific synapses [<xref ref-type="bibr" rid="CR34">34</xref>]. Local synthesis of SORLA-38b in dendrites would be in perfect agreement with such a function in cellular contact formation at the synapse, and may also relate to our observation that expression of SORLA-38b is restricted to a subset of neurons&#x02014;providing neuronal identity&#x02014;in comparison to SORLA-fl with a broader expression profile and function.</p><p id="Par62">In conclusion, for the characterization of the lowly expressed <italic>SORL1-38b</italic> we have established several methods including the development of a specific antibody, the application of E38b-specific probes for ISH and the optimization of qPCR assays. Altogether, these made the identification of an otherwise hardly detectable splice isoform possible, providing valuable information about <italic>SORL1</italic> transcriptomic profile.</p><p id="Par63">Although the study revealed novel findings about <italic>SORL1</italic>, a few limitations need to be mentioned. First, the low expression level of <italic>SORL1-38b</italic> challenged the detection of this transcript in other brain regions than the cerebellum. Thus, the implementation of more sensitive techniques, as well as the optimization of established protocols, will aim at confirming our data in non-cerebellar areas. Second, the small sample size of the cerebellum cohorts limited the analysis of <italic>SORL1-38b</italic> expression in relation to the risk T/T (SNP24) genotype. Future studies including larger cohorts will help clarifying how <italic>SORL1-38b</italic> associates with SNP24.</p></sec><sec id="Sec27"><title>Conclusions</title><p id="Par64">Here, we provide the first detailed characterization of an alternatively spliced transcript of the <italic>SORL1</italic> gene. Our results highlight two major novel findings in <italic>SORL1</italic> research: the dendritic localization of <italic>SORL1-38b</italic> transcripts and the specific reduction of E38b levels in cerebellum from AD patients despite <italic>SORL1-fl</italic> transcripts being unaltered. Altogether, these data add another layer of complexity to the understanding of <italic>SORL1</italic> biology.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec28"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40478_2021_1140_MOESM1_ESM.pdf"><caption><p><bold>Additional file 1. Figure S1</bold>: SORLA-38b is retained intracellularly in HEK cells. <bold>a</bold> Substitutions of cysteine to alanine at position 1 and 13 of the unique tail encoded by E38b do not alter the secretion of SORLA-38b in the medium. Non transf non transfected cells. <bold>b</bold> WB analysis of lysates and media from CHO cells transiently transfected with SORLA-fl, SORLA variants where stop mutations were introduced at the boundary following each 3Fn domain, or a SORLA variant lacking the cytoplasmic tail (SORLA-&#x00394;CD). Notably, constructs lacking the 3Fn5 are most strongly retained intracellularly (indicated with arrowheads).</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40478_2021_1140_MOESM2_ESM.pdf"><caption><p><bold>Additional file 2. Figure S2</bold>: Analysis of the 3&#x02032; end of <italic>SORL1-38b</italic>. Agarose gel showing 3&#x02032; RACE products for <italic>SORL1-fl</italic> and <italic>SORL1-38b</italic>. Bands indicated with arrows have been sequenced.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="40478_2021_1140_MOESM3_ESM.pdf"><caption><p><bold>Additional file 3. Figure S3</bold>: Control of RNA quality in non-AD and AD cerebella. Samples hybridization with PPIB probe showed no distinct difference in the signal from non-AD compared to AD cerebella.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="40478_2021_1140_MOESM4_ESM.pdf"><caption><p><bold>Additional file 4. Figure S4</bold>: Analysis of genetic variants affecting the expression of E38b. <bold>a</bold> Representation of the boundaries of the 3&#x02032; end locus in <italic>SORL1</italic> including localization of E38b. <bold>b</bold> eQTL mapping of <italic>SORL1</italic> gene did not show significant association with E38b expression (SNP24: rs2282649).</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to Sandra Bonnesen, Anja Aagaard, Benedicte Vestergaard, Mette Singers, and Anne Kerstine Glintborg Jensen for technical assistance. We thank NBB, Mayo Clinic and UW for providing human samples necessary to carry out this project.</p></ack><notes notes-type="author-contribution"><title>Authors' contributions</title><p>GM, MK, AMGJ, JR, RC, BEZ, CV, MMJ, NW conducted laboratory experiments. MK supervised the generation of the polyclonal antibody against SORLA-38b. IEH supervised histological analyses. MA, SL conducted experiments and analyses for the Mayo Clinic samples. NET provided oversight, resources for the Mayo Clinic studies. PLM performed the statistical analyses in R including the eQTL analysis. PNV conducted RNA-seq read alignment on human brain regions. JEY provided oversight and resources for studies conducted at University of Washington. IEH, CBV, and AN provided expert advice and assisted with data interpretation. GM, MN, and OA drafted the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Study data were provided by the following sources: The Mayo Clinic Alzheimers Disease Genetic Studies, led by Dr. Nil&#x000fc;fer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimers Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA Grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS Grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data includes samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinsons Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimers Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimers Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05&#x02013;901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinsons Research. Autopsy materials used in this study were in part obtained from the University of Washington Neuropathology Core, which is supported by the Alzheimer's Disease Research Center (AG05136), the Adult Changes in Thought Study (AG006781), the Pacific Udall Center 3P50NS062684, and DOD HU00011920008. Research in OA lab was supported by the Danish Alzheimer&#x02019;s research foundation, the M&#x000e6;rsk-M&#x000f8;ller Foundation, the Jascha Foundation, and Aarhus University Graduate School Health. Research conducted in AN lab was supported by PROMEMO&#x02014;Center for Proteins in Memory, a Center of Excellence funded by the Danish National Research Foundation (Grant DNRF133).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The results published here are in part based on data obtained from the AMP-AD Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org/">https://adknowledgeportal.synapse.org/</ext-link>). Whole genome-sequence data for 35 of the Mayo Clinic samples is available via the AD Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://adknowledgeportal.synapse.org">https://adknowledgeportal.synapse.org</ext-link>, 10.7303/syn2580853).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par65">The use of human brains from non-AD and AD individuals was approved by international review boards for Mayo, UW and NBB cohorts.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par66">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par67">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title><bold>References</bold></title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>OM</given-names></name><name><surname>Reiche</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>V</given-names></name><name><surname>Gotthardt</surname><given-names>M</given-names></name><name><surname>Spoelgen</surname><given-names>R</given-names></name><name><surname>Behlke</surname><given-names>J</given-names></name><name><surname>von Arnim</surname><given-names>CAF</given-names></name><name><surname>Breiderhoff</surname><given-names>T</given-names></name><name><surname>Jansen</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Cappai</surname><given-names>R</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Gliemann</surname><given-names>J</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Nykjaer</surname><given-names>A</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name></person-group><article-title>Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>13461</fpage><lpage>13466</lpage><pub-id pub-id-type="doi">10.1073/pnas.0503689102</pub-id><?supplied-pmid 16174740?><pub-id pub-id-type="pmid">16174740</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>OM</given-names></name><name><surname>Rudolph</surname><given-names>I-M</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name></person-group><article-title>Risk factor SORL1: from genetic association to functional validation in Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2016</year><volume>132</volume><fpage>653</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1615-4</pub-id><?supplied-pmid 27638701?><pub-id pub-id-type="pmid">27638701</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baj</surname><given-names>G</given-names></name><name><surname>Leone</surname><given-names>E</given-names></name><name><surname>Chao</surname><given-names>MV</given-names></name><name><surname>Tongiorgi</surname><given-names>E</given-names></name></person-group><article-title>Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>16813</fpage><lpage>16818</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014168108</pub-id><?supplied-pmid 21933955?><pub-id pub-id-type="pmid">21933955</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bencharit</surname><given-names>S</given-names></name><name><surname>Bin</surname><given-names>CC</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Howard-Williams</surname><given-names>EL</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name><name><surname>Zuobi-Hasona</surname><given-names>K</given-names></name><name><surname>Aukhil</surname><given-names>I</given-names></name></person-group><article-title>Structural insights into fibronectin type III domain-mediated signaling</article-title><source>J Mol Biol</source><year>2007</year><volume>367</volume><fpage>303</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.10.017</pub-id><?supplied-pmid 17261313?><pub-id pub-id-type="pmid">17261313</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blechingberg</surname><given-names>J</given-names></name><name><surname>Poulsen</surname><given-names>ASA</given-names></name><name><surname>Kjolby</surname><given-names>M</given-names></name><name><surname>Monti</surname><given-names>G</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Ivarsen</surname><given-names>AK</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>Thotakura</surname><given-names>G</given-names></name><name><surname>Vaegter</surname><given-names>CB</given-names></name><name><surname>Ertekin-Taner</surname><given-names>N</given-names></name><name><surname>Nykjaer</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>OM</given-names></name></person-group><article-title>An alternative transcript of the Alzheimer&#x02019;s disease risk gene SORL1 encodes a truncated receptor</article-title><source>Neurobiol Aging</source><year>2018</year><volume>71</volume><fpage>266.e11</fpage><lpage>266.e24</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.06.021</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/bf00308809</pub-id><?supplied-pmid 1759558?><pub-id pub-id-type="pmid">1759558</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramham</surname><given-names>CR</given-names></name><name><surname>Wells</surname><given-names>DG</given-names></name></person-group><article-title>Dendritic mRNA: transport, translation and function</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><fpage>776</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/nrn2150</pub-id><?supplied-pmid 17848965?><pub-id pub-id-type="pmid">17848965</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buxbaum</surname><given-names>AR</given-names></name><name><surname>Yoon</surname><given-names>YJ</given-names></name><name><surname>Singer</surname><given-names>RH</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name></person-group><article-title>Single-molecule insights into mRNA dynamics in neurons</article-title><source>Trends Cell Biol</source><year>2015</year><volume>25</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.05.005</pub-id><?supplied-pmid 26052005?><pub-id pub-id-type="pmid">26052005</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caglayan</surname><given-names>S</given-names></name><name><surname>Takagi-Niidome</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>F</given-names></name><name><surname>Carlo</surname><given-names>A-S</given-names></name><name><surname>Schmidt</surname><given-names>V</given-names></name><name><surname>Burgert</surname><given-names>T</given-names></name><name><surname>Kitago</surname><given-names>Y</given-names></name><name><surname>Fuchtbauer</surname><given-names>E-M</given-names></name><name><surname>Fuchtbauer</surname><given-names>A</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Takagi</surname><given-names>J</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name></person-group><article-title>Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer&#x02019;s disease mutation</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>223ra20</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007747</pub-id><?supplied-pmid 24523320?><pub-id pub-id-type="pmid">24523320</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>ID</given-names></name><name><surname>Spitzfaden</surname><given-names>C</given-names></name></person-group><article-title>Building proteins with fibronectin type III modules</article-title><source>Structure</source><year>1994</year><volume>2</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/s0969-2126(00)00034-4</pub-id><?supplied-pmid 8081748?><pub-id pub-id-type="pmid">8081748</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Charbonnier</surname><given-names>C</given-names></name><name><surname>Nicolas</surname><given-names>G</given-names></name></person-group><article-title>SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data</article-title><source>Acta Neuropathol</source><year>2019</year><volume>138</volume><fpage>173</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-01991-4</pub-id><?supplied-pmid 30911827?><pub-id pub-id-type="pmid">30911827</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciolli Mattioli</surname><given-names>C</given-names></name><name><surname>Rom</surname><given-names>A</given-names></name><name><surname>Franke</surname><given-names>V</given-names></name><name><surname>Imami</surname><given-names>K</given-names></name><name><surname>Arrey</surname><given-names>G</given-names></name><name><surname>Terne</surname><given-names>M</given-names></name><name><surname>Woehler</surname><given-names>A</given-names></name><name><surname>Akalin</surname><given-names>A</given-names></name><name><surname>Ulitsky</surname><given-names>I</given-names></name><name><surname>Chekulaeva</surname><given-names>M</given-names></name></person-group><article-title>Alternative 3&#x02019; UTRs direct localization of functionally diverse protein isoforms in neuronal compartments</article-title><source>Nucl Acids Res</source><year>2019</year><volume>47</volume><fpage>2560</fpage><lpage>2573</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1270</pub-id><?supplied-pmid 30590745?><pub-id pub-id-type="pmid">30590745</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodson</surname><given-names>SE</given-names></name><name><surname>Andersen</surname><given-names>OM</given-names></name><name><surname>Karmali</surname><given-names>V</given-names></name><name><surname>Fritz</surname><given-names>JJ</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name></person-group><article-title>Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>12877</fpage><lpage>12886</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4582-08.2008</pub-id><?supplied-pmid 19036982?><pub-id pub-id-type="pmid">19036982</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodson</surname><given-names>SE</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Lippa</surname><given-names>CF</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name></person-group><article-title>LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease</article-title><source>J Neuropathol Exp Neurol</source><year>2006</year><volume>65</volume><fpage>866</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000228205.19915.20</pub-id><?supplied-pmid 16957580?><pub-id pub-id-type="pmid">16957580</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fjorback</surname><given-names>AW</given-names></name><name><surname>Seaman</surname><given-names>M</given-names></name><name><surname>Gustafsen</surname><given-names>C</given-names></name><name><surname>Mehmedbasic</surname><given-names>A</given-names></name><name><surname>Gokool</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Militz</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>V</given-names></name><name><surname>Madsen</surname><given-names>P</given-names></name><name><surname>Nyengaard</surname><given-names>JR</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name><name><surname>Christensen</surname><given-names>EI</given-names></name><name><surname>Mobley</surname><given-names>WB</given-names></name><name><surname>Nykjaer</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>OM</given-names></name></person-group><article-title>Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>1467</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2272-11.2012</pub-id><?supplied-pmid 22279231?><pub-id pub-id-type="pmid">22279231</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>CC</given-names></name><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Hodges</surname><given-names>JR</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Sami</surname><given-names>S</given-names></name><name><surname>Hornberger</surname><given-names>M</given-names></name></person-group><article-title>Network-selective vulnerability of the human cerebellum to Alzheimer&#x02019;s disease and frontotemporal dementia</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>1527</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1093/brain/aww003</pub-id><?supplied-pmid 26912642?><pub-id pub-id-type="pmid">26912642</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holstege</surname><given-names>H</given-names></name><name><surname>van der Lee</surname><given-names>SJ</given-names></name><name><surname>Hulsman</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>TH</given-names></name><name><surname>van Rooij</surname><given-names>JG</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><name><surname>Louwersheimer</surname><given-names>E</given-names></name><name><surname>Wolters</surname><given-names>FJ</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Reinders</surname><given-names>MJ</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>Characterization of pathogenic SORL1 genetic variants for association with Alzheimer&#x02019;s disease: a clinical interpretation strategy</article-title><source>Eur J Hum Genet</source><year>2017</year><volume>25</volume><fpage>973</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2017.87</pub-id><?supplied-pmid 28537274?><pub-id pub-id-type="pmid">28537274</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>HIL</given-names></name><name><surname>Hopkins</surname><given-names>DA</given-names></name><name><surname>Mayrhofer</surname><given-names>HC</given-names></name><name><surname>Bruner</surname><given-names>E</given-names></name><name><surname>van Leeuwen</surname><given-names>FW</given-names></name><name><surname>Raaijmakers</surname><given-names>W</given-names></name><name><surname>Schmahmann</surname><given-names>JD</given-names></name></person-group><article-title>The cerebellum in Alzheimer&#x02019;s disease: evaluating its role in cognitive decline</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1093/brain/awx194</pub-id><?supplied-pmid 29053771?><pub-id pub-id-type="pmid">29053771</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>L</given-names></name><name><surname>Madsen</surname><given-names>P</given-names></name><name><surname>Moestrup</surname><given-names>SK</given-names></name><name><surname>Lund</surname><given-names>AH</given-names></name><name><surname>Tommerup</surname><given-names>N</given-names></name><name><surname>Nykjaer</surname><given-names>A</given-names></name><name><surname>Sottrup-Jensen</surname><given-names>L</given-names></name><name><surname>Gliemann</surname><given-names>J</given-names></name><name><surname>Petersen</surname><given-names>CM</given-names></name></person-group><article-title>Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>31379</fpage><lpage>31383</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.49.31379</pub-id><pub-id pub-id-type="pmid">8940146</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>IE</given-names></name><name><surname>Savage</surname><given-names>JE</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Bryois</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Steinberg</surname><given-names>S</given-names></name><name><surname>Sealock</surname><given-names>J</given-names></name><name><surname>Karlsson</surname><given-names>IK</given-names></name><name><surname>Hagg</surname><given-names>S</given-names></name><name><surname>Athanasiu</surname><given-names>L</given-names></name><name><surname>Voyle</surname><given-names>N</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Witoelar</surname><given-names>A</given-names></name><name><surname>Stringer</surname><given-names>S</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Almdahl</surname><given-names>IS</given-names></name><name><surname>Andersen</surname><given-names>F</given-names></name><name><surname>Bergh</surname><given-names>S</given-names></name><name><surname>Bettella</surname><given-names>F</given-names></name><name><surname>Bjornsson</surname><given-names>S</given-names></name><name><surname>Braekhus</surname><given-names>A</given-names></name><name><surname>Brathen</surname><given-names>G</given-names></name><name><surname>de Leeuw</surname><given-names>C</given-names></name><name><surname>Desikan</surname><given-names>RS</given-names></name><name><surname>Djurovic</surname><given-names>S</given-names></name><name><surname>Dumitrescu</surname><given-names>L</given-names></name><name><surname>Fladby</surname><given-names>T</given-names></name><name><surname>Hohman</surname><given-names>TJ</given-names></name><name><surname>Jonsson</surname><given-names>PV</given-names></name><name><surname>Kiddle</surname><given-names>SJ</given-names></name><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Saltvedt</surname><given-names>I</given-names></name><name><surname>Sando</surname><given-names>SB</given-names></name><name><surname>Selbaek</surname><given-names>G</given-names></name><name><surname>Shoai</surname><given-names>M</given-names></name><name><surname>Skene</surname><given-names>NG</given-names></name><name><surname>Snaedal</surname><given-names>J</given-names></name><name><surname>Stordal</surname><given-names>E</given-names></name><name><surname>Ulstein</surname><given-names>ID</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Hjerling-Leffler</surname><given-names>J</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>LK</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Pedersen</surname><given-names>NL</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name></person-group><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x02019;s disease risk</article-title><source>Nat Genet</source><year>2019</year><volume>51</volume><fpage>404</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0311-9</pub-id><?supplied-pmid 30617256?><pub-id pub-id-type="pmid">30617256</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Jonghe</surname><given-names>C</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Rogaeva</surname><given-names>EA</given-names></name><name><surname>Tysoe</surname><given-names>C</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Meschino</surname><given-names>W</given-names></name><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Vanderhoeven</surname><given-names>I</given-names></name><name><surname>Backhovens</surname><given-names>H</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>St George-Hyslop</surname><given-names>PH</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer&#x02019;s disease by increased Abeta42 secretion</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>1529</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.8.1529</pub-id><?supplied-pmid 10401002?><pub-id pub-id-type="pmid">10401002</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knupp</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Braggin</surname><given-names>JE</given-names></name><name><surname>Szabo</surname><given-names>M</given-names></name><name><surname>Hailey</surname><given-names>DW</given-names></name><name><surname>Small</surname><given-names>SA</given-names></name><name><surname>Jayadev</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>JE</given-names></name></person-group><article-title>Depletion of the AD risk gene SORL1 selectively impairs neuronal endosomal traffic independent of amyloidogenic APP processing</article-title><source>Cell Rep</source><year>2020</year><volume>31</volume><issue>9</issue><fpage>107719</fpage><pub-id pub-id-type="doi">10.1101/2020.01.06.896670</pub-id><?supplied-pmid 32492427?><pub-id pub-id-type="pmid">32492427</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>JL</given-names></name><name><surname>Kostadinov</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name></person-group><article-title>Protocadherins mediate dendritic self-avoidance in the mammalian nervous system</article-title><source>Nature</source><year>2012</year><volume>488</volume><fpage>517</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1038/nature11305</pub-id><?supplied-pmid 22842903?><pub-id pub-id-type="pmid">22842903</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciel</surname><given-names>R</given-names></name><name><surname>Bis</surname><given-names>DM</given-names></name><name><surname>Rebelo</surname><given-names>AP</given-names></name><name><surname>Saghira</surname><given-names>C</given-names></name><name><surname>Zuchner</surname><given-names>S</given-names></name><name><surname>Saporta</surname><given-names>MA</given-names></name></person-group><article-title>The human motor neuron axonal transcriptome is enriched for transcripts related to mitochondrial function and microtubule-based axonal transport</article-title><source>Exp Neurol</source><year>2018</year><volume>307</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2018.06.008</pub-id><?supplied-pmid 29935168?><pub-id pub-id-type="pmid">29935168</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavroudis</surname><given-names>IA</given-names></name><name><surname>Fotiou</surname><given-names>DF</given-names></name><name><surname>Adipepe</surname><given-names>LF</given-names></name><name><surname>Manani</surname><given-names>MG</given-names></name><name><surname>Njau</surname><given-names>SD</given-names></name><name><surname>Psaroulis</surname><given-names>D</given-names></name><name><surname>Costa</surname><given-names>VG</given-names></name><name><surname>Baloyannis</surname><given-names>SJ</given-names></name></person-group><article-title>Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer&#x02019;s disease</article-title><source>Am J Alzheimers Dis Other Demen</source><year>2010</year><volume>25</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1177/1533317510382892</pub-id><?supplied-pmid 20870670?><pub-id pub-id-type="pmid">20870670</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavroudis</surname><given-names>IA</given-names></name><name><surname>Manani</surname><given-names>MG</given-names></name><name><surname>Petrides</surname><given-names>F</given-names></name><name><surname>Petsoglou</surname><given-names>K</given-names></name><name><surname>Njau</surname><given-names>SD</given-names></name><name><surname>Costa</surname><given-names>VG</given-names></name><name><surname>Baloyannis</surname><given-names>SJ</given-names></name></person-group><article-title>Dendritic and spinal pathology of the Purkinje cells from the human cerebellar vermis in Alzheimer&#x02019;s disease</article-title><source>Psychiatr Danub</source><year>2013</year><volume>25</volume><fpage>221</fpage><lpage>226</lpage><?supplied-pmid 24048388?><pub-id pub-id-type="pmid">24048388</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer&#x02019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x02019;s Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1212/wnl.34.7.939</pub-id><?supplied-pmid 6610841?><pub-id pub-id-type="pmid">6610841</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motoi</surname><given-names>Y</given-names></name><name><surname>Aizawa</surname><given-names>T</given-names></name><name><surname>Haga</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Namba</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name></person-group><article-title>Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain</article-title><source>Brain Res</source><year>1999</year><volume>833</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(99)01542-5</pub-id><pub-id pub-id-type="pmid">10375696</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>G</given-names></name><name><surname>Charbonnier</surname><given-names>C</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Quenez</surname><given-names>O</given-names></name><name><surname>Bellenguez</surname><given-names>C</given-names></name><name><surname>Grenier-Boley</surname><given-names>B</given-names></name><name><surname>Rousseau</surname><given-names>S</given-names></name><name><surname>Richard</surname><given-names>A-C</given-names></name><name><surname>Rovelet-Lecrux</surname><given-names>A</given-names></name><name><surname>Le Guennec</surname><given-names>K</given-names></name><name><surname>Bacq</surname><given-names>D</given-names></name><name><surname>Garnier</surname><given-names>J-G</given-names></name><name><surname>Olaso</surname><given-names>R</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>V</given-names></name><name><surname>Deleuze</surname><given-names>J-F</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Munter</surname><given-names>HM</given-names></name><name><surname>Bourque</surname><given-names>G</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><name><surname>Redon</surname><given-names>R</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Dartigues</surname><given-names>J-F</given-names></name><name><surname>Genin</surname><given-names>E</given-names></name><name><surname>Lambert</surname><given-names>J-C</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name></person-group><article-title>SORL1 rare variants: a major risk factor for familial early-onset Alzheimer&#x02019;s disease</article-title><source>Mol Psychiatry</source><year>2016</year><volume>21</volume><fpage>831</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1038/mp.2015.121</pub-id><?supplied-pmid 26303663?><pub-id pub-id-type="pmid">26303663</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Offe</surname><given-names>K</given-names></name><name><surname>Dodson</surname><given-names>SE</given-names></name><name><surname>Shoemaker</surname><given-names>JT</given-names></name><name><surname>Fritz</surname><given-names>JJ</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name></person-group><article-title>The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>1596</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4946-05.2006</pub-id><?supplied-pmid 16452683?><pub-id pub-id-type="pmid">16452683</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Shai</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>LJ</given-names></name><name><surname>Frey</surname><given-names>BJ</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><article-title>Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>1413</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1038/ng.259</pub-id><?supplied-pmid 18978789?><pub-id pub-id-type="pmid">18978789</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pottier</surname><given-names>C</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Coutant</surname><given-names>S</given-names></name><name><surname>Rovelet-Lecrux</surname><given-names>A</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Rousseau</surname><given-names>S</given-names></name><name><surname>Legallic</surname><given-names>S</given-names></name><name><surname>Paquet</surname><given-names>C</given-names></name><name><surname>Bombois</surname><given-names>S</given-names></name><name><surname>Pariente</surname><given-names>J</given-names></name><name><surname>Thomas-Anterion</surname><given-names>C</given-names></name><name><surname>Michon</surname><given-names>A</given-names></name><name><surname>Croisile</surname><given-names>B</given-names></name><name><surname>Etcharry-Bouyx</surname><given-names>F</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Dartigues</surname><given-names>J-F</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Dauchel</surname><given-names>H</given-names></name><name><surname>Boutoleau-Bretonniere</surname><given-names>C</given-names></name><name><surname>Thauvin</surname><given-names>C</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><name><surname>Lambert</surname><given-names>J-C</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name></person-group><article-title>High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease</article-title><source>Mol Psychiatry</source><year>2012</year><volume>17</volume><fpage>875</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1038/mp.2012.15</pub-id><?supplied-pmid 22472873?><pub-id pub-id-type="pmid">22472873</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prudencio</surname><given-names>M</given-names></name><name><surname>Belzil</surname><given-names>VV</given-names></name><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Gendron</surname><given-names>TF</given-names></name><name><surname>Pregent</surname><given-names>LJ</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Overstreet</surname><given-names>KK</given-names></name><name><surname>Piazza-Johnston</surname><given-names>AE</given-names></name><name><surname>Desaro</surname><given-names>P</given-names></name><name><surname>Bieniek</surname><given-names>KF</given-names></name><name><surname>DeTure</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Biendarra</surname><given-names>SM</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Baker</surname><given-names>MC</given-names></name><name><surname>Perkerson</surname><given-names>RB</given-names></name><name><surname>van Blitterswijk</surname><given-names>M</given-names></name><name><surname>Stetler</surname><given-names>CT</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Link</surname><given-names>CD</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Boylan</surname><given-names>KB</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name></person-group><article-title>Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS</article-title><source>Nat Neurosci</source><year>2015</year><volume>18</volume><fpage>1175</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1038/nn.4065</pub-id><?supplied-pmid 26192745?><pub-id pub-id-type="pmid">26192745</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>B</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><article-title>Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles</article-title><source>Neuron</source><year>2015</year><volume>87</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.05.004</pub-id><?supplied-pmid 26139367?><pub-id pub-id-type="pmid">26139367</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockenstein</surname><given-names>EM</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Power</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer&#x02019;s disease</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>28257</fpage><lpage>28267</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.47.28257</pub-id><?supplied-pmid 7499323?><pub-id pub-id-type="pmid">7499323</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Kawarai</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Katayama</surname><given-names>T</given-names></name><name><surname>Baldwin</surname><given-names>CT</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Shibata</surname><given-names>N</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Pardossi-Piquard</surname><given-names>R</given-names></name><name><surname>Bohm</surname><given-names>C</given-names></name><name><surname>Wakutani</surname><given-names>Y</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Cuenco</surname><given-names>KT</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Pinessi</surname><given-names>L</given-names></name><name><surname>Rainero</surname><given-names>I</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Bruni</surname><given-names>A</given-names></name><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Friedland</surname><given-names>RP</given-names></name><name><surname>Inzelberg</surname><given-names>R</given-names></name><name><surname>Hampe</surname><given-names>W</given-names></name><name><surname>Bujo</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>Y-Q</given-names></name><name><surname>Andersen</surname><given-names>OM</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name><name><surname>Graff-Radford</surname><given-names>N</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Der</surname><given-names>SD</given-names></name><name><surname>Fraser</surname><given-names>PE</given-names></name><name><surname>Schmitt-Ulms</surname><given-names>G</given-names></name><name><surname>Younkin</surname><given-names>S</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name></person-group><article-title>The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>168</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/ng1943</pub-id><?supplied-pmid 17220890?><pub-id pub-id-type="pmid">17220890</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Hori</surname><given-names>O</given-names></name><name><surname>Yamaguchi</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Robinson</surname><given-names>PA</given-names></name><name><surname>Delacourte</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Furuyama</surname><given-names>T</given-names></name><name><surname>Imaizumi</surname><given-names>K</given-names></name><name><surname>Tohyama</surname><given-names>M</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name></person-group><article-title>A novel presenilin-2 splice variant in human Alzheimer&#x02019;s disease brain tissue</article-title><source>J Neurochem</source><year>1999</year><volume>72</volume><fpage>2498</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0722498.x</pub-id><?supplied-pmid 10349860?><pub-id pub-id-type="pmid">10349860</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherzer</surname><given-names>CR</given-names></name><name><surname>Offe</surname><given-names>K</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Rees</surname><given-names>HD</given-names></name><name><surname>Fang</surname><given-names>G</given-names></name><name><surname>Heilman</surname><given-names>CJ</given-names></name><name><surname>Schaller</surname><given-names>C</given-names></name><name><surname>Bujo</surname><given-names>H</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name></person-group><article-title>Loss of apolipoprotein E receptor LR11 in Alzheimer disease</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><fpage>1200</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1001/archneur.61.8.1200</pub-id><?supplied-pmid 15313836?><pub-id pub-id-type="pmid">15313836</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>V</given-names></name><name><surname>Sporbert</surname><given-names>A</given-names></name><name><surname>Rohe</surname><given-names>M</given-names></name><name><surname>Reimer</surname><given-names>T</given-names></name><name><surname>Rehm</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>OM</given-names></name><name><surname>Willnow</surname><given-names>TE</given-names></name></person-group><article-title>SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>32956</fpage><lpage>32964</lpage><pub-id pub-id-type="doi">10.1074/jbc.M705073200</pub-id><?supplied-pmid 17855360?><pub-id pub-id-type="pmid">17855360</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>NN</given-names></name><name><surname>Ottesen</surname><given-names>EW</given-names></name><name><surname>Lee</surname><given-names>BM</given-names></name><name><surname>Singh</surname><given-names>RN</given-names></name></person-group><article-title>A novel human-specific splice isoform alters the critical C-terminus of Survival Motor Neuron protein</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>30778</fpage><pub-id pub-id-type="doi">10.1038/srep30778</pub-id><?supplied-pmid 27481219?><pub-id pub-id-type="pmid">27481219</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabalin</surname><given-names>AA</given-names></name></person-group><article-title>Matrix eQTL: ultra fast eQTL analysis via large matrix operations</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts163</pub-id><?supplied-pmid 22492648?><pub-id pub-id-type="pmid">22492648</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name></person-group><article-title>The dendritic differentiation of Purkinje neurons: unsolved mystery in formation of unique dendrites</article-title><source>Cerebellum</source><year>2015</year><volume>14</volume><fpage>227</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/s12311-014-0585-0</pub-id><?supplied-pmid 25015299?><pub-id pub-id-type="pmid">25015299</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tushev</surname><given-names>G</given-names></name><name><surname>Glock</surname><given-names>C</given-names></name><name><surname>Heumuller</surname><given-names>M</given-names></name><name><surname>Biever</surname><given-names>A</given-names></name><name><surname>Jovanovic</surname><given-names>M</given-names></name><name><surname>Schuman</surname><given-names>EM</given-names></name></person-group><article-title>Alternative 3&#x02032; UTRs modify the localization, regulatory potential, stability, and plasticity of mRNAs in neuronal compartments</article-title><source>Neuron</source><year>2018</year><volume>98</volume><fpage>495</fpage><lpage>511.e6</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.03.030</pub-id><?supplied-pmid 29656876?><pub-id pub-id-type="pmid">29656876</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verheijen</surname><given-names>J</given-names></name><name><surname>Van den Bossche</surname><given-names>T</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Sanchez-Valle</surname><given-names>R</given-names></name><name><surname>Llado</surname><given-names>A</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Thonberg</surname><given-names>H</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><name><surname>Ortega-Cubero</surname><given-names>S</given-names></name><name><surname>Pastor</surname><given-names>MA</given-names></name><name><surname>Benussi</surname><given-names>L</given-names></name><name><surname>Ghidoni</surname><given-names>R</given-names></name><name><surname>Binetti</surname><given-names>G</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Fortea</surname><given-names>J</given-names></name><name><surname>de Mendonca</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>M</given-names></name><name><surname>Grau-Rivera</surname><given-names>O</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Mateiu</surname><given-names>L</given-names></name><name><surname>Dillen</surname><given-names>L</given-names></name><name><surname>Cras</surname><given-names>P</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name></person-group><article-title>A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2016</year><volume>132</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1566-9</pub-id><?supplied-pmid 27026413?><pub-id pub-id-type="pmid">27026413</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>CK</given-names></name><name><surname>Black</surname><given-names>DL</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name></person-group><article-title>The neurogenetics of alternative splicing</article-title><source>Nat Rev Neurosci</source><year>2016</year><volume>17</volume><fpage>265</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/nrn.2016.27</pub-id><?supplied-pmid 27094079?><pub-id pub-id-type="pmid">27094079</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Beckmann</surname><given-names>ND</given-names></name><name><surname>Roussos</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ming</surname><given-names>C</given-names></name><name><surname>Neff</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Fullard</surname><given-names>JF</given-names></name><name><surname>Hauberg</surname><given-names>ME</given-names></name><name><surname>Bendl</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>MA</given-names></name><name><surname>Logsdon</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Mahajan</surname><given-names>M</given-names></name><name><surname>Mangravite</surname><given-names>LM</given-names></name><name><surname>Dammer</surname><given-names>EB</given-names></name><name><surname>Duong</surname><given-names>DM</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><name><surname>Seyfried</surname><given-names>NT</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Ehrlich</surname><given-names>M</given-names></name><name><surname>Gandy</surname><given-names>S</given-names></name><name><surname>Katsel</surname><given-names>P</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Schadt</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x02019;s disease</article-title><source>Sci Data</source><year>2018</year><volume>5</volume><fpage>180185</fpage><pub-id pub-id-type="doi">10.1038/sdata.2018.185</pub-id><?supplied-pmid 30204156?><pub-id pub-id-type="pmid">30204156</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Pan</surname><given-names>N</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Z-QD</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>YA</given-names></name></person-group><article-title>Differentiation of human induced pluripotent stem cells to mature functional Purkinje neurons</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>9232</fpage><pub-id pub-id-type="doi">10.1038/srep09232</pub-id><?supplied-pmid 25782665?><pub-id pub-id-type="pmid">25782665</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>LM</given-names></name><name><surname>Wong</surname><given-names>MMK</given-names></name><name><surname>Vowles</surname><given-names>J</given-names></name><name><surname>Cowley</surname><given-names>SA</given-names></name><name><surname>Becker</surname><given-names>EBE</given-names></name></person-group><article-title>A simplified method for generating purkinje cells from human-induced pluripotent stem cells</article-title><source>Cerebellum</source><year>2018</year><volume>17</volume><fpage>419</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1007/s12311-017-0913-2</pub-id><?supplied-pmid 29397531?><pub-id pub-id-type="pmid">29397531</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>JE</given-names></name><name><surname>Boulanger-Weill</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>Woodruff</surname><given-names>G</given-names></name><name><surname>Buen</surname><given-names>F</given-names></name><name><surname>Revilla</surname><given-names>AC</given-names></name><name><surname>Herrera</surname><given-names>C</given-names></name><name><surname>Israel</surname><given-names>MA</given-names></name><name><surname>Yuan</surname><given-names>SH</given-names></name><name><surname>Edland</surname><given-names>SD</given-names></name><name><surname>Goldstein</surname><given-names>LSB</given-names></name></person-group><article-title>Elucidating molecular phenotypes caused by the SORL1 Alzheimer&#x02019;s disease genetic risk factor using human induced pluripotent stem cells</article-title><source>Cell Stem Cell</source><year>2015</year><volume>16</volume><fpage>373</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.02.004</pub-id><?supplied-pmid 25772071?><pub-id pub-id-type="pmid">25772071</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name></person-group><article-title>A novel splice variant of the cell adhesion molecule contactin 4 ( CNTN4) is mainly expressed in human brain</article-title><source>J Hum Genet</source><year>2002</year><volume>47</volume><fpage>497</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1007/s100380200073</pub-id><?supplied-pmid 12202991?><pub-id pub-id-type="pmid">12202991</pub-id></element-citation></ref></ref-list></back></article>